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ABSTRACT 
THE IMPACT OF PTSD AND HISTORY OF INVOLVEMENT IN THE 
CRIMINAL JUSTICE SYSTEM ON MEDICATION TREATMENT SUCCESS IN 
OPIOID USE DISORDER 
 
FEBRUARY 2019 
 
KIRK SANGER, B.A., KEENE STATE COLLEGE 
 
B.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
M.M., LONGY SCHOOL OF MUSIC AT BARD COLLEGE 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Lisa Chiodo, Ph.D. 
 
 
This analysis examined the impact of post-traumatic stress disorder (PTSD), 
history of trauma, and a history of involvement in the criminal justice system (CJS) on 
treatment outcomes related to medication treatment for opioid use disorder. This study 
employed a secondary analysis of data derived from a multi-state, multi-site treatment 
center focused on substance abuse and more specifically opioid use disorder treatment.  
The total sample size was 19,970 patients. The majority of the sample received treatment 
in Massachusetts, was white, and non-Hispanic. Those with PTSD accounted for 9.5% of 
the sample, while 12% had a history of trauma. Just under 1/4th of the sample had a 
history of involvement in the criminal justice system.  All individuals in the sample were 
treated with buprenorphine and were expected to participate in both individual and group 
meetings related to their treatment.      
 Patients with a history of PTSD and trauma were more adherent with 
buprenorphine, but also more likely to use opioids than those without PTSD or trauma.  
Those with CJS involvement were more medication adherent and less likely to use 
opioids than those without a CJS involvement.  All three risk groups were found to have 
viii 
significant difficulty meeting other treatment visit compliance measures such as 
attendance to individual and group visits, had overall higher rates of total number of 
encounters, and were more likely to cancel their visits.  PTSD and trauma moderated the 
relationship between CJS history and medication adherence and CJS history and opioid 
use.  PTSD and trauma moderated the relationship between CJS history and other 
compliance indicators (e.g., number of initial visits and number of induction visits).  
Gender also moderated some of the relationships examined with women having more no-
show visits, rescheduled visits more often and had higher rates of overall number of 
encounters.  Women in particular failed to attended scheduled individual and group 
treatment sessions and spent more time in care. Women also had higher rates of PTSD 
and trauma.  
 The results have implications for clinicians caring for patients with OUD and 
patients with a history of incarceration.  Assessing for and acknowledging trauma will 
allow those clinicians to implement patient-centered, trauma informed treatment models 
to deliver focused care to these specific populations that are struggling to meet treatment 
compliance measures.     
ix 
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CHAPTER 1 
OPIOID USE DISORDER, POST-TRAUMATIC STRESS, 
AND INVOLVEMENT IN THE CRIMINAL JUSTICE SYSTEM 
Introduction 
In America, 20.5 million people over the age of 12 have a Substance Use Disorder 
(SUD) (Center for Behavioral Health Statistics and Quality, 2016). Of those, over 2.1 
million people have an opioid use disorder (OUD), while over 545,000 people have a 
dependency to heroin in the U.S. (NIDA, 2015). In 2016, approximately 948,000 people 
had at a minimum tried heroin, while it was estimated that 11.8 million people had 
misused a pain reliever, most of which were opioid based (Substance Abuse and Mental 
Health Services Administration, 2017). 
Opioid addiction can lead to death, criminality, numerous co-morbidities, re-
incarceration for previously incarcerated individuals, increased exposure to HIV and 
hepatitis C, and neonatal abstinence syndrome for newborns (NIDA, 2015). 
Post-Traumatic Stress (PTS) and addiction typically co-occur (Danovitch, 2016; 
Hildebrand, Behrendt, & Hoyer, 2015). Co-occurring PTS further exacerbates an existing 
problem for those with and OUD and leads to reduced treatment outcomes (Meier et al., 
2014).  Of those 20.5 million with an SUD, approximately 1.4 million are currently 
incarcerated individuals (Fox, 2015).  Of those prisoners, approximately 40% report 
having Post-Traumatic Stress (Flatt, Williams, Barnes, Goldenson, & Ahalt, 2016).  
Those who were already exposed to trauma before incarceration also show increase of 
trauma symptoms while incarcerated (Schappell, Docherty, & Boxer, 2016). PTS itself if 
is a risk factor for increased incarceration.  Having PTS increases the odds of being 
arrested, jailed, imprisoned, and having experienced at least four or more incidents of 
trauma (Jäggi, Mezuk, Watkins, & Jackson, 2016). 
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Understanding the relationships between opioid addiction, post-traumatic stress, 
and having a history of incarceration is imperative to successfully treating individuals 
that are struggling with addiction and are participating in medication treatment (MT). 
Background of the Problem 
Opioid Use Disorder 
In the years from 1999-2015, the United States witnessed a four-fold increase in 
both the overdose deaths from opioids and heroin with a total of 33,091 deaths 
(O’Donnell, Gladden, & Seth, 2017).  Opioid related deaths now account for the largest 
number of accidental deaths in the United States. While methadone related deaths since 
2008 have decreased, there has been an increase in deaths related to heroin, illicitly 
manufactured Fentanyl, and abuse of other synthetic opioids (Rudd, Seth, David, & 
Scholl, 2016).  An increase in the prescribing of opioids over the past 15-20 years has 
contributed to increasing rates of addiction and mortality due to nonmedical use of 
prescription opioids.  There is also strong evidence that the nonmedical use of 
prescription opioids is often followed by the use of heroin (Compton, Jones, & Baldwin, 
2016). 
As of 2013, taking into account health insurance costs, loss of life and thus 
productivity, substance abuse treatment, and criminal justice costs, researchers at the 
Centers for Disease Control (CDC) estimate the U.S. economic burden to be 
approximately $78.5 billion (Florence, Zhou, Luo, & Xu, 2016).  We can only assume 
that as the opioid mortality rate continues to increase, so will this estimate. 
OUD and Post-Traumatic Stress 
Trauma is more often an antecedent to the use of opioids (Hassan, Foll, Imtiaz, & 
Rehm, 2017). Survivors of trauma, looking for a way to cope, use opioids or other drugs 
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and alcohol to self-medicate (Henwood & Padgett, 2007). Co-occurring Post-Traumatic 
Stress Disorder (PTSD) results in poorer treatment outcomes than for patients without 
symptoms of PTSD (Meier et al., 2014). More problematic is the reciprocal relationship 
between withdrawing from opioids and an increased stress response.  Those with an 
OUD, often use opioids in response to increased stress. While those withdrawing from 
opioids can experience large amounts of stress.  Therefore, refraining from opioid use 
while withdrawing can be extremely challenging and stressful.  This can often lead to 
increased use (Danovitch, 2016; Hassan et al., 2017). 
Gender Differences in OUD and PTS 
Women are at a greater risk of experiencing trauma through sexual violence, 
emotional and physical abuse, and experiencing trauma at younger age.  There are 
marked gender differences within OUD both for patients with and without PTS. PTS also 
has a role in partially mediating the relationship of women’s substance use with violent 
offending (Howard, Karatzias, Power, & Mahoney, 2017). As women with PTS continue 
to use substances and commit violence, they are as a consequence, more likely to have a 
history of incarceration (Komarovskaya, Booker Loper, Warren, & Jackson, 2011).  
Women are more likely to be diagnosed with post-traumatic stress, substance abuse, and 
depression (Al-Rousan, Rubenstein, Sieleni, Deol, & Wallace, 2017). 
While there has been variation in outcomes for those in concurrent treatment for 
SUD and PTS, there have been significant improvements for those receiving trauma 
focused dual treatment with attrition rates being the same across all groups (Killeen, 
Back, & Brady, 2015).  Clinicians agree that there is a need for concurrent treatment, 
however are not in agreement as to how treatment should progress, especially in cases of 
severe trauma.  The concern is notably whether or not the person re-experiences trauma 
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during therapy and thus desires to re-abuse substances to relieve said trauma (L. M. 
Najavits, Kivlahan, & Kosten, 2011). 
Persons with Involvement in the Criminal Justice System and PTSD 
While 18% of the overall incarcerated population will present with some mental 
health diagnosis  (Al-Rousan et al., 2017), incarceration itself has implications to expose 
inmates to trauma while incarcerated (Beck, Berzofsky, Caspar, & Krebs, 2013).  People 
who have been incarcerated or are presently incarcerated often feel unsafe, exhibit 
increased anti-social behavior, and symptoms of trauma due to circumstances related to 
but not limited to childhood trauma, domestic violence, and military violence pre-
incarceration (Schappell et al., 2016).   
OUD and Involvement in the Criminal Justice System 
Entering the penal system in the United States while suffering with an OUD 
presents one of several situations and depends whether that person is incarcerated in a 
federal prison or a state run correctional facility.   Not providing an MT at the beginning 
of incarceration has long-term implications for increased mortality and suicidality in the 
first few weeks of the incarceration experience (Larney et al., 2014; Rivlin, Ferris, 
Marzano, Fazel, & Hawton, 2013). 
Federal Prison 
Following a framework of abstinence from opioids, the United States Bureau of 
Prisons (BOP) directs clinicians within the federal prison system on a prescribed method 
for detoxification of inmates who present with a current SUD (Federal Bureau of Prisons, 
2014).   
Methadone is the recommended course of treatment until the cessation of 
withdrawal symptoms, followed by a 10% taper daily until the Methadone is 
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discontinued. Typically, adjunct treatment is included only for withdrawal symptoms in 
the form of Clonidine, as well as anti-inflammatories, antipyretics, anti-emetics, and anti-
anxiety medication, but not a long-term opioid medical maintenance treatment.  This will 
at times allow for a controlled withdrawal and symptom management, however does not 
assist long-term recovery during their incarceration or after re-entry.   
State Correctional Facilities 
Each state has their own policy regarding the use of MT within the correctional 
system.  Depending on the particular state, some correctional facilities provide MT, while 
others do not (Aronowitz & Laurent, 2016). Treatment with continued opioid 
maintenance agonists such as methadone, or antagonists such naltrexone or a mix of the 
two, buprenorphine, is still not prevalent within the U.S. correctional system even though 
these methods are effective evidence-based medical practices.  There are few instances 
where jails or prisons are providing viable treatments for incarcerated populations with an 
OUD.  Treating inmates during their incarceration has lasting effects during the 
incarceration experience as well as post-release (Rich et al. 2015). 
Persons with Involvement in the CJS and Medication Treatment  
Exiting the correctional system with an OUD significantly puts individuals at 
higher risk for increased medical issues and re-incarceration, but also death (Binswanger 
et al., 2016; Marsden et al., 2017; Merrall et al., 2010).  The risk appears to be heightened 
for younger people, women more specifically.  In a study of 42,015 recently released 
individuals, 14,920 of which were young prisoners (<25yr), Van Dooren, Kinner, & 
Forsyth (2013) determined that the younger group was less at risk for mortality than 
older, previously incarcerated individuals.  However, poisoning by drugs was the leading 
cause of death for the younger group with men at 43% and women 50%.  More 
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specifically, the younger group, when compared to peers in their community at similar 
ages, were six times as likely to die.  The women in the younger group were 20 times as 
likely to die then their community peers. 
Studies are limited examining the outcomes of MT among incarcerated 
individuals. There are some however that demonstrate the effectiveness of MT both in the 
correctional setting and upon re-entering the community. These studies have 
demonstrated positive results in terms of overall health, reduction in mortality, and 
reduction in re-offending post-release (Degenhardt et al., 2014; Gisev et al., 2015; 
Larney, Toson, Burns, & Dolan, 2012; Marsden et al., 2017). While MT has been shown 
to be successful as a treatment modality for incarcerated prisoners evidenced by a lower 
recidivism rate, a decrease in cravings for opioids, and lower rates of sexually transmitted 
infections (Aronowitz & Laurent, 2016). 
It is clear from previous research that MT is successful for some groups.  
However, when considering the effects of PTSD, trauma, and an involvement in the 
criminal justice system, it becomes clear that there is not a complete understanding of 
what those effects mean for those that have an OUD while also living with PTSD, a 
history of trauma, or a past involvement in the criminal justice system.  Understanding 
these relationships may allow practitioners that ability to deliver more applicable 
treatment to these groups. 
Significance of the Study 
Opioid addiction can lead to death, criminality, numerous co-morbidities, re-
incarceration for previously incarcerated individuals, increased exposure to HIV and 
hepatitis C, and neonatal abstinence syndrome for newborns (NIDA, 2015). 
Approximately 30% of the people in seeking treatment for their opioid addiction have a 
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diagnosis of PTSD (Ecker, Hundt, Ecker, & Hundt, 2017).  Additionally, 50% of those 
people seeking treatment for OUD have an involvement in the criminal justice system 
(Winkelman et al., 2016) and 80% have a diagnosis related to an anxiety disorder (Brady, 
Haynes, & Killeen, 2013). 
MT has demonstrated success among those in treatment in the form of agonist and 
antagonist therapy for long-term recovery (Hser, Evans, Grella, Ling, & Anglin, 2015b).  
This approach to MT is often combined with individual or group counseling techniques 
aimed at allowing the patient to change their neurobiology as well as their cognitive 
relationship to opiates.  At times this has increased retention within combined treatment 
programs (Timko, Schultz, Cucciare, Vittorio, & Garrison-Diehn, 2016).  However, this 
may actually inhibit successful treatment of PTSD as this may interrupt the development 
of coping skills (Danovitch, 2016; Saunders et al., 2015a).  Understanding these 
relationships more clearly will enable clinicians to intervene more appropriately when 
presented with someone with co-occurring PTSD and participating in MT.  
Understanding how these interactions affect those with involvement in the criminal 
justice system who are in the process of recovery will aid in long term success. 
Developing a clearer understanding and framework for treatment within this 
smaller subset of the population may allow clinicians to treat other groups of individuals 
suffering from the combination of PTSD and OUD.  Veterans, sexual abuse survivors, 
refugees, or other individuals living with PTSD and OUD will benefit from the 
approaches and practices that can instituted with the knowledge from this proposed study. 
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Purpose 
The purpose of this study is to explore the relationships between Opioid Use 
Disorder, Post-Traumatic Stress, involvement in the criminal justice system, and MT 
treatment success. 
Study Aims and Hypotheses 
To achieve the study goal, this proposal will examine the following aims and 
hypotheses in a sample of Opioid Use Disorder patients receiving MT.  For all aims, the 
following outcome variables will be examined: treatment compliance (the number no 
show visits, number maintenance visits, number of initial visits, number of rejoin visits, 
number of induction visits, number of group visits, number of no show group visits, 
number of group cancellations, number of rescheduled visits, number of interruptions, 
number of other encounters, total time in care, and the time since the last visit), 
medication adherence, and drug use (opioids, cocaine, THC, methadone, 
benzodiazepines, alcohol, amphetamines, cocaine, other drugs. Other drugs included 
PCP, barbiturates, methamphetamines, and ecstasy. 
Aim 1: To compare outcomes of Medication treatment (MT) success in patients with 
elevated post-traumatic stress (PTS) and patients without PTS. 
H1a-m. Patients with evidence of PTS will have lower rates of treatment compliance 
than patients without evidence of PTS. 
 
 
H1n. Patients with evidence of PTS will have a lower rates of medication adherence 
compared to patients without evidence of PTS. 
 
PTS+ 
PTS+ 
 
¯ Medication Adherence  
¯ Treatment Compliance 
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H1o. Patients with evidence of PTS will have an increase in drug use than patients 
without evidence of PTS. 
 
 
Aim 2: To compare outcomes of Medication treatment (MT) success in patients with 
a history of trauma (Trauma+) and patients without a history of trauma. 
H2a-m. Patients with evidence of Trauma will have lower rates of treatment 
compliance than patients without evidence of Trauma. 
 
 
H2n. Patients with evidence of Trauma will have a lower rates of medication 
adherence compared to patients without evidence of Trauma. 
 
H2o. Patients 
with evidence of Trauma will have an increase in drug use than patients without 
evidence of Trauma. 
 
 
Aim 3: To compare outcomes of Medication treatment (MT) success in patients 
with a history of involvement with the criminal justice system (CJS) and patients 
without a history of involvement in CJS. 
PTS+ ­ Drug Use  
Trauma+ 
Trauma+ 
 
¯ Medication Adherence  
¯ Treatment Compliance 
Trauma+ ­ Drug Use  
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H3a-m. Patients with involvement in the criminal justice system will have lower rates 
of treatment compliance than patients without involvement in the criminal justice 
system. 
 
 
H3n. Patients with involvement in the criminal justice system will have lower rates of 
medication adherence compared to patients without involvement in the criminal 
justice system. 
 
 
H3o. Patients with an involvement in CJS will have an increase in drug use than patients 
without involvement in the criminal justice system. 
 
 
 
Aim 4. To examine if PTS status moderates the relationship between involvement in 
the criminal justice system and Medication Treatment success. 
H5a-m. The relationship between involvement in the criminal justice system and 
provider visit compliance will be moderated by PTS status. 
 
 
 
 
 
Involvement in CJS+ 
Involvement in CJS+ 
Involvement in CJS+ ¯ Treatment Compliance 
¯ Medication Adherence 
Treatment Compliance 
PTS+ 
Involvement in CJS+ ­ Drug Use 
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H5n. The relationship between involvement in the criminal justice system and 
medication adherence will be moderated by PTS status. 
 
 
 
 
 
H5o. The relationship between involvement in the criminal justice system and drug 
use will not be moderated by PTS status. 
 
 
 
 
 
Aim 5. To examine if trauma status moderates the relationship between involvement 
in the criminal justice system and Medication Treatment success. 
H6a-m. The relationship between involvement in the criminal justice system and 
treatment compliance will be moderated by trauma status. 
 
 
 
 
 
Involvement in CJS+ 
PTS+ 
¯ Medication Adherence 
Involvement in CJS+ 
PTS+ 
↑ Drug Use 
Involvement in CJS+ ¯ Treatment Compliance 
Trauma+ 
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H6n. The relationship between involvement in the criminal justice system and 
medication adherence will be moderated by trauma status. 
 
 
 
 
 
H6o. The relationship between involvement in the criminal justice system and drug 
use will not be moderated by trauma status. 
 
 
 
 
 
In addition to the above aim, the influence of gender on the impact of PTS+ or trauma on 
the relationship between buprenorphine and treatment success was examined. 
Summary 
Given the substantial personal and societal impact of opioid use, understanding 
factors that might impact MT treatment is critical.  Understanding if factors such as PTS 
and CJS status will lead to poorer OUD treatment success provides an opportunity for the 
development of interventions to increase treatment retention and success for all 
individuals with OUD. In addition, understanding the relationship of PTS, CJS and MT 
treatment will allow clinicians the opportunity to provide evidence-based treatment to a 
very deserving population.  
Involvement in CJS+ 
Trauma+ 
¯ Medication Adherence 
Involvement in CJS+ 
Trauma+ 
↑ Drug Use 
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CHAPTER 2 
 
REVIEW OF LITERATURE AND THEORETICAL FRAMEWORK 
 
This chapter provides on overview of the complexities of opioid use disorder 
(OUD), co-occurring post-traumatic stress (PTS), and having a history of incarceration.  
This is a review of the literature as it pertains to the relationships of OUD, post-traumatic 
stress, incarceration, and medical management of OUD.  I utilize a theoretical framework 
developed by Lazarus and Folkman – the Transactional Stress theory as it relates to 
treatment of opioid use disorder will having co-occurring post-traumatic stress, trauma, 
and an involvement in the criminal justice system. 
Introduction 
In America, 20.5 million people over the age of 12 have a Substance Use Disorder 
(SUD) (Center for Behavioral Health Statistics and Quality, 2016). Of those, over 2.1 
million people had an opioid use disorder (OUD), while over 545,000 people are 
dependent on heroin in the U.S. (NIDA, 2015).  Opioid addiction can lead to death, 
criminality, numerous co-morbidities, re-incarceration for previously incarcerated 
individuals, increased exposure to HIV and hepatitis C, and neonatal abstinence 
syndrome for newborns (NIDA, 2015).  In 2016, approximately 948,000 people had at a 
minimum tried heroin, while it was estimated that 11.8 million people had misused a pain 
reliever, most of which were opioid based (Substance Abuse and Mental Health Services 
Administration, 2017). 
Post-Traumatic Stress (PTS) and addiction typically co-occur (Danovitch, 2016; 
Hildebrand et al., 2015). Co-occurring PTS further exacerbates an existing problem for 
those with and OUD and leads to reduced treatment outcomes (Meier et al., 2014).  Of 
those 20.5 million with a SUD, approximately 1.4 million are currently incarcerated 
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individuals (Fox, 2015).  Of those prisoners, approximately 40% report having Post-
Traumatic Stress (Flatt et al., 2016).  Those who were already exposed to trauma before 
incarceration also show an increase of trauma symptoms while incarcerated (Schappell et 
al., 2016). PTS itself is a risk factor for increased incarceration.  This is especially 
evident for black men.  Having PTS increases the odds of being arrested, jailed, 
imprisoned, and having experienced at least four or more incidents of trauma (Jäggi et al., 
2016). 
Understanding the relationships between opioid addiction, post-traumatic stress, 
and having a history of incarceration is imperative to successfully treating individuals 
that are struggling with PTS, addiction and are receiving medication treatment (MT). 
Background of the Problem – Opioid Use 
Opioid use in not a new phenomenon.  The medicinal origins of opioid use can be 
traced back as early as 1,500 B.C. (Brownstein, 1993). During antiquity, opium poppies 
used on statues and in paintings, represented sleep and death (Tekiner & Kosar, 2016).  
More formalized in the sixteenth-century, the social use of ‘laudanum’, a potent mix of 
opium (later replaced by morphine) and alcohol, was reserved for the social elite 
(Heyman, 2009).  Physicians, as they do today, played a role in perpetuating the uses and 
efficacy of opiates for numerous ailments (Kulich & Loeser, 2011).  These were at times 
reasonable and at other times bordered on the farfetched.  These ailments included: pain, 
sleep, headaches, menstrual cramping, diarrhea, insanity, and even used to treat 
tuberculosis among other infective diseases (Postler & Waisel, 1997). 
While opium was already widely used, it gained recognition as an addictive 
substance in the late eighteenth-century and was responsible for creating a schism in the 
trade economy between Britain and China.  As Britain pushed more opium into China in 
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exchange for silver, more of the Chinese population became dependent on the substance.  
China became well aware of the physical and mental distress enacted on their citizens 
who had become overwhelmed by the substance causing conflict in what would go on to 
be known as the Opium Wars (Caquet, 2015). 
This has continued to present day where the reasons people use and abuse opioids, 
be it prescription or illegal, are varied. Some come to opioid use as a way to relieve pain 
from surgery, cancer, or other physical ailments (Moryl et al., 2017; Yorkgitis & Brat, 
2018).  Of those, some come to abuse opioids as a way to supplement their pain 
management that they believe is not being properly controlled.  For some, opioids are a 
natural progression from less potent drugs.  Others use opiates as a recreational 
experience, merely trying it out due to shear curiosity and to feel the sedating effects of 
the drug.  As will be examined further, others use opiates for the relief of mental anguish 
and trauma (Stumbo et al., 2017). 
Opioid Use Disorder 
In the years from 1999-2015, the United States witnessed a four-fold increase in 
both the overdose deaths from opioids and heroin with a total of 33,091 deaths (Dowell, 
Arias, Kochanek, & al, 2017; O’Donnell et al., 2017).  Opioid related deaths now account 
for the largest number of accidental deaths. While methadone related deaths since 2008 
have decreased, there has been an increase in deaths related to heroin, illicitly 
manufactured Fentanyl, and abuse of other synthetic opioids (Rudd et al., 2016).  An 
increase in the prescribing of opioids over the past 15-20 years has contributed to 
increasing rates of addiction and mortality due to nonmedical use of prescription opioids.  
There is also strong evidence that the nonmedical use of prescription opioids is often 
followed by the use of heroin (Compton et al., 2016). 
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As of 2013, taking into account health insurance costs, loss of life and thus 
productivity, substance abuse treatment, and criminal justice costs, researchers at the 
Centers for Disease Control (CDC) estimate the U.S. economic burden to be 
approximately $78.5 billion (Florence et al., 2016).  We can only assume that as the 
opioid mortality rate continues to increase, so will this estimate. 
The Diagnostic and Statistical Manual of Mental Disorders fifth edition (5th ed.; 
DSM–5; American Psychiatric Association [APA], 2013)1 describes Opioid Use Disorder 
(OUD) as a persistent, chronic, use of opioids that over the course of a 12-month period 
is characterized by at least two criteria (Appendix B). 
Concurrent with the DSM-V criteria, the American Society of Addiction 
Medicine (ASAM) describes any addiction in terms of the chronic nature in which these 
occur. ASAM further views the brain and neural network as the chief contributor to 
addiction as the brain has the inherent capacity to influence motivation, reward, craving, 
and need to satisfy both physical and mental discomfort (American Society of Addiction 
Medicine, 2015). 
Treatment Options in Opioid Use Disorder 
Treatment for OUD presently exists in two major forms.  These are abstinence-
based models and models that include Medication Treatment (MT). 
Abstinence Model of Opioid Treatment 
Abstinence models are based solely on the idea that people will recover from 
opioid use without the assistance of opioid agonists or partial agonists.  The colloquial 
term often used is that the person withdrew from opioids ‘going cold turkey’.  If this 
course of treatment is decided upon, the ASAM recommends that some medication be 
                                               
1 Diagnostic and Statistical Manual of Mental Disorders : DSM-5. (2013) (see Appendix B) 
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used to treat withdrawal symptoms and that this is done in conjunction with personalized, 
psychosocial treatment. Abstinence based treatment is not the recommended treatment 
based on evidence-based practice and current research findings that using Medically 
Assisted Treatment is not only safer, but reduces relapse and mortality among other 
outcomes (American Society of Addiction Medicine, 2015; Bart, 2012). 
Medication Treatment  
Medication treatment (MT) is a course of treatment that began when those with an 
Opioid Use Disorder were first given medicine in the form of an opioid agonist to help 
prevent relapse and relieve the immense symptoms felt when withdrawing from opioids.  
This was first initiated with the use of morphine and decreasing doses of heroin to taper 
people off of opioids.  Pharmaceutical oxycodone, codeine, and Demerol were also tried 
initially, but were disregarded as they tended to still have the sedating effect of short 
acting opioids and increased tolerance as their use continued.  Methadone, which is the 
preferred treatment modality with the highest rates of opioid reductions, decreased 
mortality, and retention in treatment (Substance Abuse and Mental Health Services 
Administration, 2018) approved was then developed as a longer acting opioid that did not 
cause the euphoria of morphine and heroin, or increase the tolerance as earlier opioids 
had, yet still managed to decrease cravings and did not sedate patients as did earlier short 
acting opioids (Center for Substance Abuse Treatment, 2012). 
Buprenorphine/Naloxone is a recent addition to the options that clinicians have in 
terms of treating people using an opioid maintenance treatment.  This drug in particular 
has the benefit of seeking the same mu receptors as opioids, yet, does not have the same 
effect once it is in place as the naloxone aspect is an opioid antagonist and lowers the 
potential for the same euphoria and sedating effects of opioids (Center for Substance 
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Abuse Treatment, 2012). Buprenorphine has been shown to be a successful medicinal 
treatment for OUD in reducing cravings, relapse, and mortality (Ohtani, 2007). 
Naltrexone has been available since the late 1960’s but has only seen an increase 
in use as a once a month extended-release injectable.  This particular form of MT is used 
as a non-agonist medicine that blocks opioid substances from entering mu receptor sites 
in the brain.   The injectable is thus the preferred method of administration as this 
prevents the patient from having to remember to take their pill every day, has a greater 
half-life, allows for a greater reduction in cravings, is more expensive initially but then 
evens out over time, and relates to longer periods of recovery (Substance Abuse and 
Mental Health Services Administration, 2016). 
While counseling is the preferred treatment concurrent with opioid substitution 
treatment, there are still mixed findings in terms of efficacy of counseling treatment.  For 
instance, Fiellin et al. (2006) found that during a study of Buprenorphine distribution at 
single or multiple times per week, that when combined with short or long-term 
counseling, there were no differences between groups that suggested either counseling 
method had a significant effect on prevention of relapse.  Fiellin et al. did note that the 
type of counseling was not prescribed and were not tailored to each individual patient. 
Similarly, Weiss & Rao (2017) conducted a study that compared treatment for 
prescription opioid users who either received opioid drug counseling and those who did 
not.  Their findings demonstrated that the counseling group was not more successful in 
treatment.  However, they did note after further analysis of the counseling groups that 
those who had a history of heroin use were more successful in the combined 
counseling/Buprenorphine than those with a history of heroin use who were not in the 
combined group. 
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Conversely, Moore et al. (2016) found that Cognitive Behavioral Treatment 
(CBT) was a successful approach when combined with physician managed 
Buprenorphine treatment for those with prescription opioid use, but not for those who had 
used heroin. 
Anxiety/OUD 
While PTS dominates the focus of today’s psychiatric worldview, PTS is only one 
disorder grouped under the umbrella of Anxiety disorders which is grouped in the AXIS 
1 domain of the DSM-V.  The AXIS 1 delineation denotes that all disorders in this group 
are the most common psychiatric disorders in our culture (DSM-5., 2013). 
An 2009 systematic review by Fatséas, Denis, Lavie, & Auriacombe (2010) using 
DSM-IV criteria revealed a lifetime prevalence of anxiety among those with an OUD 
ranging from 26%-35%.  Fatseas et al. (2010) note that of these studies, there are two 
major hypotheses for anxiety to present as a diagnosis.  When an anxiety diagnosis 
emerges initially then is followed by a diagnosis of OUD, often opioids or other 
substances are used to self-medicate to relieve the symptoms and feelings or anxiety.  In 
the contrary sequence, OUD emerges as the first diagnosis with anxiety following as the 
second diagnosis as a resultant symptom of being in opioid withdrawal through recovery. 
Researchers investigating the prevalence of co-occurring psychiatric diagnoses 
among those with an initial OUD diagnosis in Spain, found that anxiety was the highest 
co-occurring disorder (53%) (Roncero et al., 2016).  Other research examining the 
consequences of anxiety on co-occurring diagnoses found that individuals with an 
anxiety disorder are more likely to seek out prescription opioids.  In a study reviewing 
medical office prescriptions for Schedule II opioids from 1995-2010, those with an 
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anxiety disorder were 11 times more likely (OR=10.99) to use prescription opioids 
(Olfson, Wang, Iza, Crystal, & Blanco, 2013). 
Treatment of Co-occurring Anxiety and OUD  
Treating co-occurring anxiety and OUD medically presents problems for the 
clinician looking to quell both anxiety and OUD cravings as well as other symptoms.  
General treatment recommendations for anxiety is to try first-line medications that 
include serotonin reuptake inhibitors (SRI) first.  These do not always work well in this 
population and it is therefore recommended to try benzodiazepines (BZD) as a second 
line medication. This approach is typically affective at decreasing symptoms.  The 
problem is that BZDs are not recommended for use for people with SUDs, especially 
OUD (Craske & Bystritsky, 2017). 
That recommendation appears to be followed by the majority of physicians.  In a 
recent study of people using BZDs, only 27.8% of them received them from their 
physician (not all were in opioid treatment), while 51.3% bought them on the street and 
the remaining 20.9% took them from or were given them by a friend or family member.  
If those with an OUD are misusing and abusing BZDs as well, it is clear that it may not 
be under the care of a physician (Stein, Anderson, Kenney, & Bailey, 2017). 
An earlier synthesis of 200 articles conducted by Jones, Mogali, & Comer (2012) 
found a multitude of complications resulting from concurrent use of both opioids and 
BZDs.  They noted increased use of BZDs for heroin users entering treatment and up to 
75% prevalence rate of using BZDs for those in opioid treatment using buprenorphine.  
This is supported by a recent study by Morley, Ferris, Winstock, & Lynskey (2017) 
examining misuse and abuse of prescription opioids. Utilizing the Global Use Survey, 
containing data from several nations, they held country of residence constant in their 
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model and were able to determine that those using illicit opioids as well as BZDs had an 
OR=6.49 of abusing their prescribed opioid analgesic. 
One promising outlook is that the treatment for OUD may in fact decrease 
symptoms of anxiety.  Ahmadi & Jahromi (2017) hypothesized that one dose of 
buprenorphine would decrease anxiety in opioid dependent patients.  Here we can see 
that OUD was not even the focus, lessening anxiety was the aim.  They found that 
regardless of dosage amount, using one dose of buprenorphine lessened anxiety 
significantly over a seven day period.  This study did not address what place anxiety had 
within the realm of OUD.  They were not asking whether or not anxiety was an 
antecedent to OUD, a consequence of OUD, or influenced the outcomes of treatment for 
OUD. 
Post-Traumatic Stress 
Post-Traumatic Stress (PTS) is the consequence of having experienced an 
overwhelming physical or emotional event or events that causes the body and mind to 
later react as though it were under the same stressors of the initial event or cumulative 
events.  Both the trauma itself and the symptoms that follow from PTS are highly 
subjective.  What one person perceives as a traumatic event, may not be the same for 
another person.  Additionally, after experiencing the same event and being traumatized 
by it, people will react to it and exhibit different symptoms from one another.  Symptoms 
can include but are not limited to: anxiety, social withdrawal, depression, avoidance of 
feelings, tremors, flashbacks, gastrointestinal disturbances, somatic pain and discomfort, 
etc. (Regel & Joseph, 2010). 
Noted trauma psychiatrist and researcher, Bessel Van Der Kolk (2014), states that 
recovery for victims of trauma is difficult as the trauma itself often changes features 
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within the brain and specifically the pre-frontal cortex.  This area of the brain is essential 
to making decisions needed to making decisions, plan, and make corrections in behavior. 
Trauma Leading to PTSD 
Not all traumatic experiences (TE) are created equal and not all who experience 
TEs have the same outcome.  Experiencing at least one TE is actually a relatively 
common experience for people around the globe with one study showing up to 66.5% of 
participants meeting criteria for at least one TE in their lifetime (Elhai et al., 2012).  Why 
some people then suffer from Post-Traumatic Stress (PTS) while others do not is a 
question that many are attempting to answer. 
Noting a lack of definitive evidence for predictability of PTSD following TE, a 
group of international scholars has developed one promising method aimed at 
determining predictors of Post-Traumatic Stress Disorder (PTSD) among those who have 
had a TE.  The researchers utilized data from the World Health Organization’s (WHO) 
World Health Survey. Of the 126,096 respondents, 42,634 reported at least one TE over 
their lifetime.  Exploratory factor analysis narrowed the 29 subtypes of TEs down to 5 
factors: “exposure to organized violence, participation in organized violence, 
interpersonal violence, sexual-relationship violence, and other life-threatening TEs” 
(Kessler et al., 2014, p. 267). 
Applying regression modeling and machine learning algorithms allowed the 
group to predict that the highest risk for developing PTSD was a TE involving sexual-
relationship violence.  This type of TE accounted for 12.1% of the overall TEs in the 
population but accounted for 32.9% of the overall proportion of PTSD among the group.  
The 2nd highest sub-group was a sixth category named Network Traumatic Experiences 
which included: unexpected death of a loved one, life-threatening illness of child, other 
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traumatic experience of loved one.  This accounted for 22.5% of all TEs and 29.7% of the 
proportion of PTSD (Kessler et al., 2014).  What is striking is that participating in 
organized violence such as combat, purposely/accidently caused a death, witnessed death, 
etc., accounted for 21.3% of the TEs, yet only 11.2% of the proportion of PTSD.  As 
expected from previous studies, Kessler et al. (2014) also determined that TE was related 
to an increased risk of a psychiatric diagnoses; individuals with TE were 27 times more 
likely to have a PTSD diagnosis and just over two times more likely to have a diagnoisis 
of generalized anxiety disorder. 
For those with prior or current psychiatric diagnoses and a TE, PTSD is more 
predictable (Powers et al., 2014).  While examining predictability of PTSD for patients 
admitted to a level I trauma center, they were able to predict PTSD with 76.3% accuracy 
at 3-month follow-up.  Powers et al. (2014) found their predictors to be age (younger), 
gunshot wounds, and number of premorbid psychiatric conditions.  Two critiques of this 
study is that they were focused soley on physical injury and negated sexual violence as a 
physical injury and thus it was not included in their model.  Additionally, during their 
screening process, 12% of participants tested positive for drugs and were also given the 
AUDIT-C as an alcohol screening.  The drugs finding was not included in their model. 
Though they included alcohol and found it to be not predictive of PTSD.  However, the 
inclusion of premorbid psychiatric conditions continues to represent a major predictor for 
each study reviewed. 
Furthermore, Carlson, Palmieri, & Spain (2017) working on the predictability of 
PTSD as well, found another set of risk factors following trauma to be predictive of 
PTSD. These were negative thoughts, post-trauma life stress, post-trauma social 
constraints, post-trauma social support, acute stress symptoms, and childhood home life.  
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When these risk factors were subjected to sensitivity and specificity analysis, they found 
a high sensitivity or the probability that the risk factors are present in those that have 
PTSD (0.85 - 0.97). The specficify or the probability that risk factors were not present in 
the people that did not have PTSD was also acceptable (0.68 – 0.83) (Rosner, 2015). 
From Trauma Experience to PTSD Diagnosis 
While research is promising in terms of how TEs contribute to PTSD, the 
importance should be placed on how clinicians are utilizing the aforementioned research 
in identifying risk factors, screening, and then diagnosing properly.  Liebschutz et al. 
(2007) conducted a study at an urban primary care office screening 509 patients for TEs, 
PTSD, and psychiatric comorbidities and then compared those findings to the electronic 
medical record (EMR) for each participant for diagnostic comparison.  Consistent with 
Elhai et al. (2012) they found that 79% of the participants had at least one TE and 65% 
had more than one TE.  They determined that 39% met the DSM-IV criteria for lifetime 
PTSD and 23% met the criteria for current PTSD.  Consistent with previous studies 
(Carlson et al., 2017; Olaya et al., 2015; Powers et al., 2014) was the finding that 91% of 
those with PTSD had at least one co-morbidity. 
Of these participants, 64% of those with anxiety, had a lifetime PTSD diagnosis, 
42% had a current diagnosis of PTSD.  Those with substance use had a lifetime PTSD 
prevalence of 52%.  The most alarming finding of the study is that when comparing these 
findings to the participant’s EMR, they found that only 11% of those with PTSD had a 
congruent diagnosis reflected in their EMR.  In a recent review (Greene, Neria, & Gross, 
2016) of studies examining the prevalence of PTSD in primary care settings, prevalence 
rates in studies ranged from 2 - 27% and detection rates from 2.4 – 46.5% when 
comparing study diagnosis with EMR similar to Liebschutz et al. (2007). 
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Opioid Use Disorder and Post-Traumatic Stress 
Survivors of trauma, looking for a way to cope, use opioids or other drugs and 
alcohol to self-medicate (Hser, Evans, Grella, Ling, & Anglin, 2015a). However, 
Henwood & Padgett (2007) remind readers that the purely self-medication hypothesis is 
one that should be viewed as suspect and may include multiple risk factors and co-
morbidities.  Trauma is often an antecedent to the use of opioids. Utilizing data from the 
National Epidemiologic Survey on Alcohol and Related Conditions III, Hassan, Foll, 
Imtiaz, & Rehm (2017) demonstrated that individuals with a PTS diagnosis earlier in life 
were three times as likely to develop an OUD compared to those who had an OUD but 
were never diagnosed with PTS.  Controlling for age, education, marital status, living 
area, self-reported general health, and employment status still resulted in a 65% increase 
in risk. 
One of the reasons PTS is detrimental to those with an OUD is the increased 
capacity for misuse of the opioids they receive.  Cochran, Hruschak, Bacci, Hohmeier, & 
Tarter (2017) performed latent class analysis on data from 333 people in community 
pharmacies specifically looking for subgroups that may be more predisposed to using 
prescription opioids improperly. One subgroup identified was a group of individuals with 
co-occurring PTS, depression, and report of pain in the past four weeks.  Among this 
group, 44% had misused their prescription opioids and were six times more likely to do 
so than other groups identified. 
Symptoms of PTS with OUD 
Even the degree to which symptoms of PTS are experienced are affected by 
having a co-occurring OUD.  Meier et al. (2014) found that the symptoms of PTS were 
influenced by overall substance use and even more by opioid use.  Of their sample of 573 
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subjects, they found that of the 218 people using prescription opioids, 47% met the 
diagnostic criteria for PTS.  They were also able to determine that symptom severity 
increased with polysubstance abuse and increased depending on substances. 
Increased PTS symptom severity and increased substance use disorder (SUD) was 
also demonstrated in an much earlier study conducted by Brown, Stout, & Gannon-
Rowley (1998) on the perception of the relationship of a person’s own substance use 
disorder (SUD) and their co-occurring PTS or trauma symptoms.  They determined that 
people with co-occurring SUD/PTS tended to view these two disorders as related to one 
another.  Though a small sample, 77% of their participants felt that when their trauma 
symptoms worsened, there was a direct impact on their substance use.  Similarly, 78% 
responded that if their trauma symptoms resolved or improved, so did their substance use. 
Treatment of OUD with Co-occurring PTS 
Treatment of opioid use disorder (OUD) while co-occurring with PTS is 
complicated and may require multiple frameworks. Beyond the reasons for why one uses 
opioids, or the inherent diversity in the demographics of people who use opioids, Killeen, 
Back, & Brady (2015) provide a review of the mix of obstacles that impacts treatment of 
both PTS/OUD together and individually.  One key barrier to treatment is that at times 
there is a lack of commitment to treat both OUD and PTS equally or concurrently.  This 
is compounded often by an organization’s misunderstanding of a particular paradigm and 
lack of a method to ensure fidelity to the prescribed treatment of concurrent OUD/PTS.  
In some parts of the country, counselor turnover is high due to a perceived stigma of 
treating patients with SUD while simultaneously valuing the treatment of those with PTS. 
Just these issues alone make it difficult to provide a sustained, evidence-based treatment.  
 27 
Thus, co-occurring Post-Traumatic Stress Disorder (PTS) can result in reduced treatment 
outcomes than for patients without symptoms of PTS (Meier et al., 2014). 
However, there have been instances where sustained OUD/PTS treatment has 
been shown to be effective.  Tofighi et al. (2015) found that due to early treatment 
evaluations at admission to a buprenorphine clinic, they were able to treat PTS 
concurrently with OUD.  They evaluated treatment outcomes for subjects who were in 
concurrent OUD treatment and were participating in psychiatric treatment for their PTS 
both pre and post Hurricane Sandy.  They noted that although subjects missed follow-up 
appointments and missed opportunities to acquire their buprenorphine, at 6-months post 
Hurricane Sandy, this particular group showed no increase in positive drug screens. 
Peirce, Brooner, King, & Kidorf (2016) evaluated subjects who had an alarming 
average of 18 lifetime traumatic events.  They found that when subjects had a traumatic 
event during treatment, this doubled their risk of non-compliance with treatment in the 
month following the event.  Even more profound was in the months after the initial 
month, this risk doubled again. 
Stress Response in OUD/PTSD  
The reciprocal relationship between withdrawing from opioids and an increased 
stress response is problematic for those with OUD.  While withdrawing from opioids 
increases stress, the converse is also true that those with OUD use opioids to reduce 
stress.  Constantinou et al. (2010) compared the stress levels and attentional bias of users 
of heroin against ex-users and non-users.  The current users of heroin demonstrated not 
only a significantly higher level of stress during the study than ex-users and non-users, 
but also had significantly higher levels of drug craving during the study.  An additional 
finding of the study was that the current user group had a significantly higher level of 
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attentional bias during short and long-term exposure to toward heroin related subject 
matter utilized during the study.  They posit that stress potentially leads to more 
attentional bias and craving in users which directly relates to an inability to resist and 
remain abstinent.   This is reflective of Lazarus & Folkman’s (1984) concept of appraisal 
within stress and coping.  As a current user is appraising a stressful situation or event, if 
attentional bias is focused on the use of an opioid, this attention limits the ability to cope 
and reduce stress, thus leading potentially to the use of an opiate. 
Withdrawing from opioids can cause large amounts of stress.  Therefore, 
refraining from opioid use while withdrawing can be extremely challenging and stressful.  
This can often lead to increased use (Danovitch, 2016; Hassan et al., 2017).  
Demographic Differences in Treatment of OUD/PTS 
Gender 
It should be noted that women are at greater risk of experiencing trauma through 
sexual violence, emotional and physical abuse, and at younger age.  There are marked 
gender differences within OUD both for patients with and without PTS. PTS also has a 
role in partially mediating the relationship of women’s substance use with violent 
offending (Howard et al., 2017). As women with PTS continue to use substances and 
commit violence, they are as a consequence, more likely to have a history of 
incarceration (Komarovskaya et al., 2011).  In a study of 573 adult subjects, Meier et al. 
(2014) demonstrated that women who have PTS and OUD not only experience almost 
three times the severity of PTS symptoms as men, but also 30.1% of the women in the 
sample compared to 18% of the men had co-occurring PTS and OUD.   
While there has been variation in outcomes for those in concurrent treatment for 
SUD and PTS, there has been significant improvements for those receiving trauma 
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focused dual treatment with attrition rates being the same across all groups (Killeen et al., 
2015).  Clinicians agree that there is a need for concurrent treatment, however are not in 
agreement as to how treatment should progress, especially in cases of severe trauma.  The 
concern is notably whether or not the person re-experiences trauma during treatment and 
thus desires to re-abuse substances to relieve said trauma (L. M. Najavits et al., 2011). 
OUD among Persons with an Involvement in the CJS 
Having an involvement in the Criminal Justice System (CJS) has the potential to 
increase the risk of traumatic experiences and thus PTS (Anderson, Geier, & Cahill, 
2016; Harner, Budescu, Gillihan, Riley, & Foa, 2015; Kouyoumdjian et al., 2015).  
Additionally, entering the penal system in the United States while suffering with an OUD 
can further exacerbate an already difficult situation.   Incarceration presents one of 
several situations and depends whether that person is incarcerated in a federal prison or a 
state run correctional facility. 
OUD in Federal Prison 
The United States Bureau of Prisons (BOP) publishes a clinical treatment manual 
that directs clinicians within the federal prison system on a prescribed method for 
detoxification of inmates who present with a current SUD.  This manual has not been 
updated since 2014 (Federal Bureau of Prisons, 2014).  The manual follows a theoretical 
framework of abstinence from opioids and provides little instruction on how to achieve 
this within 5-10 days. 
If medical based treatment is provided, the recommended course of treatment is 
the use of Methadone until the cessation of withdrawal symptoms, followed by a 10% 
taper daily until the Methadone is discontinued. Typically, adjunct treatment is included 
only for withdrawal symptoms in the form of Clonidine, as well as anti-inflammatories, 
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antipyretics, anti-emetics, and anti-anxiety medication, but not a long-term opioid 
maintenance MT.  In fact, the document states if an inmate enters with a current 
Buprenorphine use, they are to be detoxified of it and then discontinued. 
In addition, the Health Services division of the BOP releases a pharmaceutical 
formulary document that describes what the pharmacies in federal prisons will have on 
hand and what they are allowed to dispense and for what reasons.  In regards to the use of 
Buprenorphine, the document reads, “will only be approved for detoxification, [NOT] for 
pain or maintenance treatment” (Federal Bureau of Prisons Health Services, 2016, p.17).  
Allowing Buprenorphine for a period of detoxification may allow for a controlled 
withdrawal and symptom management, however does not assist long-term recovery 
during their incarceration or after re-entry (Hser et al., 2015b). This is especially 
important for those using heroin, as it has been demonstrated that abstinence episodes last 
longer each successive time and are more effective when accompanied by sustained long-
term MT (Nosyk, Anglin, Brecht, Lima, & Hser, 2013).  It should also be noted that the 
BOP manual lacks any reference to a counseling or therapeutic model that an inmate may 
utilize in the recovery. 
OUD in State Correctional Facilities 
Each state has their own policy regarding the use of MT within the correctional 
system.  In some states, correctional facilities provide MT maintenance, while others do 
not. Rikers Island Correctional Facility (Rikers) in New York is one facility that has 
treated their inmates who present with OUD with MT, more specifically Methadone since 
as early as 1987.  While in other facilities an inmate is provided no medical treatment for 
opioid withdrawal (Aronowitz & Laurent, 2016). 
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Besides ignoring the ethical imperative to humanely treat individuals and provide 
autonomy in healthcare decisions (Ludwig & Peters, 2014; Wakeman, 2017), not 
providing an MT at the beginning of incarceration has long-term implications for 
increased mortality and suicidality in the first few weeks of the incarceration experience 
(Gisev et al., 2015; Larney et al., 2014; Rivlin et al., 2013).  A report authored by the 
Public Health Department of Massachusetts, noted greater than 50% risk of mortality 
when comparing the opioid deaths of former inmates (869.4/100,000 people) in the state 
to non-inmate opioid deaths in the state (15.4/100,000 people) (Massachusetts 
Department of Public Health, 2016). 
As noted in the prior section, treatment with continued opioid maintenance 
agonists or antagonists, is still not prevalent within the U.S. correctional system even 
though these methods are effective evidence-based medical practices.  There are 
instances where this is occurring and confirming that this a successful, viable treatment 
methodology for incarcerated populations with an OUD. 
Treating inmates during their incarceration has lasting effects during the 
incarceration experience as well as post-release.  Rich et al., (2015) performed a 
randomized controlled trial involving inmates in a Rhode Island correctional facility.  
These inmates were randomly assigned to one of two groups upon admission: one a 
Methadone forced withdrawal group (the current practice in those facilities), and the 
second, a Methadone continuation group.  The findings are supportive of other studies.  
The continuation group was more likely to seek out and follow-up with Methadone 
treatment post-incarceration.  One striking difference from other studies in regard to 
mortality, was that the one opioid related death post-release was from the continuation 
group.  Finally, in another small sample feasibility study, buprenorphine treatment 
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initiated while incarcerated was related to continued treatment after release (Zaller et al., 
2013). 
Persons with an Involvement in the CJS and MT 
Exiting the correctional system with an OUD significantly puts individuals at 
higher risk for increased morbidity and mortality as well as re-incarceration (Binswanger 
et al., 2016; Marsden et al., 2017; Merrall et al., 2010).  The risk is higher for younger 
people, women more specifically.  In a study of 42,015 recently released individuals, 
14,920 of which were young prisoners (<25yr), Van Dooren, Kinner, & Forsyth (2013) 
determined that the younger group was less at risk for mortality than older, previously 
incarcerated individuals.  However, poisoning by drugs was the leading cause of death 
for the younger group with men at 43% and women 50%.  In this sample, younger 
individuals were six times more likely to die than their community peers; younger 
women were 20 times more likely to die. 
Treating those with OUD at the beginning of their incarceration with MT has 
been demonstrated to significantly affect their health, mortality, and re-offending post-
release.  Researchers for the Australian government compiled four sets of data pertaining 
to mortality, re-entry of prisoners, addiction, and a general offender database (Gisev et 
al., 2015).  One significant finding was that initiating MT at the entry to incarceration 
resulted in a 93% reduction in unnatural deaths (drug overdose) within the first four 
weeks of post-release. Combining records of post-release mortality, re-entry, and MT 
continuation, Gisev et al. further determined that drug use accounted for death the most.  
Examining post-release differences between those in MT and those not in MT, those in 
MT had the smallest crude mortality rate (CMR) at 6.4 per 1,000-person years and those 
not in MT had a CMR of 36.7 per 1,000 person years. 
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Likewise, Marsden et al. (2017), found that initiating MT upon release also had a 
similar effect.  Utilizing a prospective cohort of 15,141 subjects across 32 British 
National correctional facilities, they found a significant relationship between initiating 
MT upon release and a decline in mortality.  With 18 drug related deaths within the first 
four weeks post-release, only three were found to be within the group currently 
prescribed MT. 
Degenhardt et al. (2014), demonstrated similar findings with a cohort of 16,453 
people who had a total of 60,101 prison releases over a period of 12 years.  Half of this 
group was given MT upon release.  Of the 1050 deaths that occurred, 135 (13%) 
happened within the first 4 four weeks.  They found that exposure to MT in the form of 
opioid substitution, limited the death rate by 78% for those re-entering prisoners within 
the first month of re-entry. 
One possible way to mitigate these issues is to have the incarcerated population 
with a dependence on opioids, initiate MT upon arrival.  While MT has been shown to be 
successful as a treatment modality for incarcerated prisoners evidenced by a lower 
recidivism rate, a decrease in cravings for opioids, and lower rates of sexually transmitted 
infections (Aronowitz & Laurent, 2016), understanding the effect that PTS will have on 
the relationship of MT and having a history of incarceration, will allow clinicians to treat 
those who suffer from OUD and PTS more effectively.  Since MT has not become 
commonplace in incarcerated settings, few studies have examined MT in the prison 
setting (Hedrich et al., 2012). 
Of the few studies related to describing the outcomes of MT on incarcerated 
individuals both in the correctional setting and upon re-entering the community, initiating 
MT while incarcerated has been found to have significant effects on re-incarceration after 
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having re-entered the community.   Larney, Toson, Burns, & Dolan (2012), utilized a 
random control trial to assess MT in incarcerated men who inject heroin. The researchers 
found that while overall, initiating MT pre-release, did not significantly reduce re-
incarceration. However, those that stayed in the prescribed MT after release reduced their 
re-incarceration risk by 20%.  In contrast, while Gordon et al. (2017) demonstrated a 
longer period of time in treatment for those initiating Buprenorphine pre-release vs. those 
starting post-release, they did not demonstrate a significant difference in relation to using 
opioids post-release and re-incarceration. This may be attributed to a lack of linking 
patients to treatment, monitoring subjects closely, and a short time period of induction to 
dosing of only 3-6 months pre-release (Vocci et al., 2015).  In addition, there was 
insufficient study power and there was not a true control group of a re-entered people not 
taking MT. 
Buprenorphine appears to be favored by those with and OUD that are incarcerated 
when compared to methadone.  When treatment was initiated during incarceration using 
either buprenorphine or methadone, individuals preferred buprenorphine (Awgu, Magura, 
& Rosenblum, 2010) and subjects further stated that they would be more willing to use 
buprenorphine post-release.  This preference for buprenorphine was based on subject 
responses that buprenorphine was more effective, presented less side effects, reduced 
cravings more than methadone, and that it took effect quicker.  In an additional study, 
those subjects treated with buprenorphine pre-release were more likely to continue to 
arrive for their appointments at a community treatment center more than the methadone 
treatment group.  They also found that 5 of their methadone group switched post-release 
and switched from the methadone treatment to the buprenorphine group (Magura et al., 
2009).  This preference for remaining in treatment and a greater affinity for 
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buprenorphine may be related to concern on the part of the subjects to limit withdrawal 
from methadone, and a more effective response. 
Many studies have primarily focused on re-incarceration, mortality, and treatment 
continuation as general outcomes (Hedrich et al., 2012).  Outcomes such as cravings, 
relapses, retention of employment, and co-occurring PTS symptoms, should be 
considered to further understand the implications of starting MT programs in more jails 
and prisons. 
Gender Differences in MT during Incarceration 
The literature examining the impact of MT during incarceration has identified 
some difference based on gender.  For example, Farrell & Marsden (2008) found that 
women had a risk of mortality that was 10 times greater than men in the first week of 
release from prison and only dropped to 8 times greater at 52 weeks post-release.   When 
women initiated treatment with buprenorphine while incarcerated, Gordon et al. (2017) 
determined that women were more likely to resist using opioids for a greater length of 
time than their male cohort, suggesting that if more women were treated while 
incarcerated, there may be the opportunity to decrease mortality post-release. 
Persons with a History of Incarceration and PTS 
Of the 20.5 million with a Substance Use Disorder (SUD), approximately 1.4 
million are currently incarcerated individuals (Fox, 2015).  Of those prisoners, 
approximately 40% report having Post-Traumatic Stress (Flatt et al., 2016).  This is 
especially true for both men and women entering incarcerated settings have also been 
shown to have higher rates of childhood trauma (Giarratano, Ford, & Nochajski, 2017). 
Those who were exposed to trauma before incarceration also show an increase of trauma 
symptoms while incarcerated (Schappell et al., 2016). 
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Diagnosis of PTS within the penal system is laden with issues and leads to 
inaccuracies in terms of who is and is not diagnosed with PTS.  Depending on the prison, 
some provide a self-report questionnaire to ascertain whether or not this person has been 
diagnosed with PTS or experiences symptoms of PTS (Beck et al., 2013).  This leads to 
problems when people who over report diagnoses with PTS require additional resources 
and care, while some who have not been formally diagnosed yet experience symptoms of 
PTS and often underreport these symptoms (Oguntoye & Bursztajn, 2009). 
Reporting on the diagnosis of 201 women prisoners with or without PTS, Warren, 
Loper, & Komarovskaya (2009), found that 97% experienced some type of trauma in 
their life and those who met the diagnostic criteria for PTSD reported 6.6 trauma 
experiences, compared to 4.8 experiences for those who did not meet criteria.  While 
there was a variety of traumas experienced, they determined that it was the cumulative 
number of traumas that appeared contribute to a diagnosis of PTSD, not trauma type. 
Warren et al. (2009) pointed out that symptoms of PTS often occur with other 
diagnoses or without a specific diagnosis and warn against diagnosing inmates just from 
a report of symptoms.  It should be noted that these women also felt that experiencing a 
trauma such as a mugging, rape, or physical abuse, described these experiences as being 
as traumatic to them as witnessing an act of violence towards another person.  This is 
closely supported by Swopes, Davis, & Scholl (2017) who reported finding that the 
incarcerated women in their study rated witnessing an act of violence third behind being 
assaulted with a deadly weapon and unwanted sexual contact before the age of 13.  They 
also found that women rated witnessing trauma more traumatic than unwanted sexual 
contact before the age of 18 and being attacked without a weapon. 
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For women with PTS and also being incarcerated, witnessing trauma is likely and 
therefore concerning as this has implications to expose inmates to further trauma while 
incarcerated (Beck et al., 2013; Hagan et al., 2017). People who have been incarcerated 
or are presently incarcerated often feel unsafe, exhibit increased anti-social behavior, and 
symptoms of trauma due to circumstances related to, but not limited to, childhood 
trauma, domestic violence, and military violence pre-incarceration (Schappell et al., 
2016). 
Re-entry Into the Community with PTS 
Experiences before, during, and after incarceration all contribute to individual 
levels of levels of PTS.  Schappell et al. (2016) assessed the trauma symptoms of 100 
men who had previously been incarcerated.  Being victimized during incarceration 
demonstrated a significant relationship to higher levels of PTS.  Having a mental health 
issue prior to incarceration was also found to moderate the severity of victimization and 
thus PTS. Men that re-entered their communities but did not live in a half-way house or 
with family experienced the highest amount of PTS.  Remarkably, of the 100 men in the 
study, only 11 stated that they had not witnessed or been the victim of violence while 
incarcerated. 
Results from an epidemiologic study of 5008 people by Anderson, Geier, & 
Cahill (2016) confirm similar findings to Shappell et al. (2016) that having more 
traumatic life events was related to an increase in having a history of incarceration.   This 
study also examined trauma type. Being in a car accident was one of the weaker 
predictors of incarceration (AOR=1.7), while being physically beaten was the strongest 
predictor (AOR=3.5). Having a trauma experience that potentially would potentially lead 
to death resulted in a three time increase in the likelihood of incarceration. Shappell et al. 
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also found that individuals with a lifetime diagnosis of PTSD were twice as likely to be 
incarcerated than those without PTSD.  Limiting further trauma experiences and linking 
to treatment post-release is imperative to reducing not only further opioid use, but further 
involvement with the criminal justice system. 
While PTS itself if is a risk factor for increased incarceration, this is especially 
evident for black men.  Having PTS increases the odds of being arrested, jailed, 
imprisoned, and having experienced at least four or more incidents of trauma (Jäggi et al., 
2016).  Anderson, Geier, & Cahill (2016) demonstrated that incarcerated black men also 
were at greater risk for PTS than their peers who had did not have a history of 
incarceration. 
Gender Differences of PTS and Incarceration 
While 18% of the overall incarcerated population will present with some mental 
health diagnosis, gender differences are also present.  Women are more likely to be 
diagnosed with post-traumatic stress, substance abuse, and depression (Al-Rousan et al., 
2017).  Incarcerated women with PTS have experienced trauma in a variety of ways 
before entering jail or prison.  This ranges from unwanted sexual contact from a young 
age, witnessing acts of violence toward others or animals, torture, and physical assault 
(Harner et al., 2015). While Giarratano et al. (2017) found there to be no significant 
gender differences in terms of the occurrence of behavioral problems associated with PTS 
between male and female inmates, women displayed more PTS symptoms compared to 
men as well as a greater risk of use of heroin or cocaine.  Men with PTS have been noted 
to seek out after-care treatment post release for their PTSS more than men without PTS 
(Kubiak, 2004).   An explanation for this could be that they were victimized during 
incarceration that they did not face previously in the community.  Since women have 
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historically been victims of trauma pre-incarceration more than men, release to the 
community where they have previously experienced trauma may contribute to greater 
relapse and further exacerbating PTS. 
Persons with an Involvement in the CJS, PTS, and OUD 
As demonstrated earlier, PTS and OUD combined, as well as incarceration and 
OUD combined, have the potential to seriously disrupt individual and public health.  
Results are mixed in regard to studies that include incarceration or a history of 
incarceration, mental illness, and opioid use.  This could present challenging treatment 
issues for incarcerated populations with PTS that are re-experiencing trauma or living 
through initial trauma while incarcerated and then later treated for OUD after release.  As 
this is a group that may not be receiving psychiatric treatment while incarcerated as well 
as not receiving MT, it is possible that this population would be tough to recruit to 
treatment as well as maintain compliance with treatment protocols. 
For instance, Swopes, Davis, & Scholl (2017) struggled to find between-group 
differences in their dual treatment of women experiencing co-occurring PTS/OUD while 
incarcerated.  While the women in the study were able to decrease cognitions of PTS 
post-treatment, there was not a significant between-groups interaction that showed 
marked differences. 
Greenberg & Rosenheck (2014) found a significant relationship between mental 
health, substance use, and re-incarceration.  They determined that while race/ethnicity 
and recent immigration did not present a greater risk for a history of incarceration, being 
male, not having finished high school, and being young were positively associated with 
having and incarceration history.  They also determined that those with a SUD were at 
greater risk for longer incarcerations. 
 40 
Robertson et al. (2018) compared the use of methadone, buprenorphine, and 
naltrexone for those with an OUD, mental illness diagnosis and involvement to some 
extant in the criminal justice system.  Their results showed only a 3% risk in the 
incarceration rate for those being treated with buprenorphine compared to the comparison 
group.  However, the methadone and naltrexone groups showed a 39% and 62% greater 
risk of incarceration respectively. 
Functional status/outcomes (Substance Abuse and Mental Health Services 
Administration, 2012) are still not prevalent measures in follow-up studies with this 
particular sub-group. For instance, Zlotnick, Johnson, & Najavits (2009) studied 
PTS/SUD treatment outcomes while utilizing a cognitive behavioral treatment developed 
by Najavits (2002) called Seeking Safety.  Using a randomized control trial of treatment 
with Seeking Safety compared to treatment as usual, they studied a sample of women 
recently incarcerated who had co-occurring PTS/SUD.  Although appearing 
underpowered in their sample size of n=49, they employed common measures including 
addiction assessment tools and self-reports of treatment satisfaction, and re-incarceration 
(the only functional status outcome).  They did determine that 22% of those in the 
treatment group returned to prison within 6 months, compared to 45% in the non-
treatment group. 
Racial Differences in Incarceration, PTS, and OUD 
While Greenberg & Rosenheck (2014) found that black men had a 13% higher 
incarceration rate and found that black men were 2.5 times more likely to have longer 
sentences to fulfill.  This could pose several problems for black men, but especially black 
men that have an OUD.  As they stay incarcerated for longer, more than likely without 
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treatment, and have the possibility of experiencing more trauma, they are potentially at 
greater risk for having a tough recovery after they are released. 
Theoretical Framework 
To understand the relationships between trauma, coping and outcomes of opioid 
treatment, Lazarus and Folkman’s Transactional Stress theory will be applied as a 
framework within which to view OUD treatment for patients with potential maladaptive 
coping strategies developed while dealing with co-occurring OUD and PTS. 
Lazarus and Folkman (1984) situate their Transactional Stress theory within the 
framework of people experiencing stress in a myriad of ways throughout their individual 
life cycle.  While not developed initially for addiction-based contexts, this theory is 
especially pertinent to apply to addiction treatment and this particular study.  The current 
study hypothesizes that stress, in the form of traumatic stress from life experiences and 
particularly stress of incarceration is what in effect causes individuals to not only use 
opioids in the first place or exacerbates a chronic use, but also restricts them from 
recovering in the same manner of those who have not experienced stress in the same 
manner. 
Stress 
The traditional concept of stress is that stress is a stimulus followed simply by a 
mental or physiological response.  Lazarus and Folkman (1984) reject this concept in 
favor of a more fluid and flexible one.  This concept of stress is focused on the 
relationship between person and environment.  Depending on both of these variables, the 
confirmation of stress is based on the cognitive appraisal of the specific person and not 
people in general.  The underlying use of stress theory for Lazarus and Folkman is that 
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individuals possess varying resources and either respond or fail to respond to stress and 
traumatic experiences accordingly.   
Appraisal 
For Lazarus and Folkman (1984), cognitive appraisal is the formation of thoughts 
regarding a specific environment or situation based around the idea of well-being and 
limiting vulnerability.  People appraise events in regard to whether or not the results will 
bring them harm or will be beneficial.  It should be noted that these appraisals are 
ongoing and are not always fully thought out decisions, but cognitively happening at all 
moments.  They delineate three specific forms of appraisal: irrelevant, benign-positive, 
and stressful. 
Irrelevant 
Irrelevant appraisal is the act of appraising a situation and deciding that this has 
no inherent cause for concern or excitement and therefore is disregarded. 
Benign-Positive 
Appraising an encounter or environment and deciding that this is in fact beneficial 
instead of threatening to well-being, would be seen as Benign-Positive. 
Stressful 
Appraising a situation as stressful includes three potential concepts: fearing some 
harmful experience, one that brings a threat, and one that potentially presents a challenge.  
Harm can arrive in a multitude of ways i.e. physical, mental, social, or loss of a loved 
one.   Threatening situations cause stress because they have yet caused harm but have the 
potential to do so and this in and of itself creates an anticipatory stress.  Challenges can 
be both beneficial and harmful. Perceiving a challenge inherently allows us to first think 
of the benefit that we can derive from successfully navigating the challenge.  However, 
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Lazarus and Folkman (1984) point out that challenge and threat can be extremely similar 
as a cognitive appraisal.  One may see potential benefits from a challenge, but then also 
immediately formulate the idea of the threat and vulnerability of not succeeding within 
the challenge. Appraisals can also be regarded as time-oriented or successive. 
Lazarus and Folkman (1984) consider appraisals of similar situations to be 
primary, secondary, and reappraisals.  As one continues to reappraise situations, they may 
employ more effective coping mechanisms and thus find successful resolutions to 
stressful situations.  These are indeed meaningful. Instead of a group of automatic 
behaviors that are a programmed response. 
Coping 
Traditionally, coping was identified as the way that people control a situation or 
their response to a situation to limit the overall affect it may have on them.   Lazarus and 
Folkman (1984) define coping as, “constantly changing cognitive and behavioral efforts 
to manage specific external and/or internal demands that are appraised as taxing or 
exceeding the resources of the person” (p. 141).  They chose this definition based on the 
premise that this understanding of coping included the ability for the individual to change 
within different situations rather than having one trait that automatically gave them a 
defined way of responding to the situation. This is a similar concept to resilience. 
Mechanism of Theory 
Lazarus and Folkman (1984) describe appraisal and coping as mediating 
processes.  Antecedents of these processes include the person’s sense of control and the 
environment in which demands, or harm are perceived.  These initiate mediating 
processes to be enacted as the person moves through successful iterations of appraising 
and then enacts certain coping strategies.  The connection between emotion and coping is 
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also described by Folkman & Lazarus (1988) as a bi-directional processes.  It is not 
coping that affects emotion or vice versa. Their view is that one can affect the other in 
either direction.  Furthermore, Folkman & Lazarus found coping or lack of coping to be a 
mediator of emotion in stressful encounters.  These lead to immediate effects related to 
physiological and psychological changes.  This then potentially promotes long-term 
effects such as somatic health/illness or positive/negative social functioning. This is 
illustrated in Table 1. 
 
 
Table 1.  A theoretical schematization of stress, coping, and adaptation (Lazarus and 
Folkman, 1984, p.305). 
 
Causal 
Antecedents 
Mediating 
Processes 
 
Immediate Effects Long-Term 
Effects 
Person variables: 
values 
commitments 
 
Beliefs: sense of 
control  
 
Environment: 
situational 
demands, 
constraints 
 
Resources: (e.g., 
social network) 
 
Ambiguity of harm 
& imminence of 
harm 
Primary appraisal 
  
Secondary appraisal 
  
Reappraisal  
 
Coping: 
Problem-focused 
Emotion-focused 
Seeking, obtaining, 
and using social 
support 
 
Physiologic 
changes 
 
Positive/Negative 
feelings 
 
Quality of 
encounter outcome 
Somatic 
health/illness 
 
Morale (well-being) 
 
Social Functioning 
 
Relation of Theory to OUD 
 Managing emotions and employing effective coping strategies has been shown to 
provide a protective factor against substance use.  Employing a problem-based coping 
strategy rather than an emotionally-based coping strategy reduces poor self-efficacy and 
 45 
thus allows a person to work through their stressor rather than distance themselves and 
use substances as a means of coping (Rabani Bavojdan, Towhidi, & Rahmati, 2011).  
Bavojdan et al. (2011) also demonstrated that those who perceived themselves in less 
control of their lives and sensing that the external environment was more in control of 
them, were more likely to have a substance use disorder (SUD).  This has been further 
supported by the work of Hassanbeigi, Askari, Hassanbeigi, & Pourmovahed (2013). 
Counseling/Training in OUD 
Lazarus and Folkman (1984) posit that training a person to first recognize  
stressors and appraise them thoughtfully and from a problem-centered framework will 
allow them manage emotions and cope more effectively.  This is supported by the 
Substance Abuse and Mental Health Services Administration (SAMHSA) and the 
American Society of Addiction Medicine (ASAM), both of which encourage counseling 
as an adjunct to medication treatment (MT) (American Society of Addiction Medicine, 
2015; Substance Abuse and Mental Health Services Administration, 2016).  
Theoretically speaking, as any person experiences a stressor, they would first 
likely appraise that from an emotional point of view.  They would then make a second 
appraisal which would ideally be derived from a problem-focused viewpoint which 
would then inform a decision of how one wants to act in this situation.  This is delineated 
as both a cognitive decision as well as a physiologic reaction to the stressor. This would 
ideally result in a positive long-term adaptation that would allow that person to have a 
beneficial or adaptive reaction to that particular stressor that next time it occurred in their 
life (Figure 1). 
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Figure 1. Theory applied to successful coping and appraisal. 
Medication Treatment, PTS, and Involvement in the CJS 
Using opioids in the setting of experiencing symptoms of post-traumatic stress 
represents a lack of coping and appraisal based on the inevitability of harm.  To reduce 
harm and vulnerability, the individual turns to opioids as a coping strategy.  Withdrawing 
and not using opioids represents both a threat for the individuals included in MT.  The 
threat perceived can be viewed in a social or neurobiological context.  Socially, the 
perceived threat is that one will have to inevitably live among potential stressors without 
using opioids as a coping strategy.  Neuro-biologically, the individual risks the threat of 
not only feeling ill, but also failing to re-establish their normal neurologic state free of 
opioids.  This study further hypothesizes that for a large set of people in recovery, there 
may by multiple instances of relapse due to perceived stress and lacking fundamental 
appraisal and coping mechanisms. 
Incarceration, as hypothesized in this study, has the potential to be acted upon by 
post-traumatic stress.  PTS has the potential to generate further stress and a lack of coping 
and appraisal upon the person with an incarceration history. 
However, as Lazarus and Folkman (1984) remind the reader, threats can also 
represent positive challenges.  For instance, consider an individual participating in MT at 
an addiction treatment center.  Upon appraising the outcomes after staying free of drugs, 
Antecedent
(Trauma)  
1st 
Appraisal
(Emotional)
2nd 
Appraisal
(Problem 
focused)
Decision Long-term adaptation
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one may perceive the inherent benefits of remaining employed, visiting or living with 
their children, feeling healthy, and reviving intimate relationships. 
Lazarus and Folkman (1984) theorize that the continued appraisal and coping, 
will inevitably lead to long-term adaptation and proper management of emotions.  Again, 
this relates to those within MT.  As relapse happens, the general desire is for the length of 
time between each relapse to progressively become longer and longer.  This can 
contribute to recovery in that Lazarus and Folkman’s long-term adaptation allows the 
person to continually make re-appraisals that will determine how a person will cope with 
their environment and stressor at a later trajectory in their lives. This is demonstrated in 
Figure 2. 
 
Figure 2. Theory applied to successful coping and appraisal within OUD treatment. 
As a person with OUD and PTS are in MT, when they meet a potential stressor 
the first action is to appraise this from an emotional viewpoint.  They then reappraise this 
with a problem-solving framework that allows them to employ coping strategies to 
effectively remain drug free and continue with MT.  This continuation of MT without the 
use of opioids allows them to continue adapting to life without a reliance on opioids. 
Theoretical Framework Summary 
Lazarus and Folkman’s (1984) Transactional Stress theory as outlined in Stress, 
Appraisal, and Coping theorizes that human beings live within an environment that is 
inherently stressful for individual reasons.  As people navigate this environment, they are 
Antecedent
(Opioid 
depenence 
and Post-
Traumatic 
Stress)   
1st 
Appraisal
(potential 
for added 
stress and 
relapse) 
2nd 
Appraisal
(weighing 
opioid use 
vs. 
abstaining
Continued 
medication 
treatment
Adaptation 
to non-
reliance on 
opioids 
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continually (consciously or unconsciously) reacting to these stressors.  If successfully 
experiencing these stressors, people inevitably appraise these situations based mostly 
from a problem-solving perspective.  They theorize that as people appraise from only an 
emotional perspective, they may not make purposeful, coping oriented decisions which 
can contribute to maladaptive mental and physical health. 
As people in recovery are often experiencing an onslaught of stress on a daily, 
sometimes, minute to minute basis, viewing their capacity to appraise situations from the 
Transactional Stress model allows us to understand recovery and relapse from an emotion 
and problem-solving framework.  As people in recovery continue to calm their brain and 
thus nervous system with medication treatment, they generate physiologic adaptation to 
stress. From here they can also learn to appraise their stressors appropriately from an 
emotional viewpoint and then move to an appropriate problem-based strategy to move 
themselves forward.  The goal is that by moving forward consistently, the person 
develops resilience and a long-term adaptation to that stress that would require less and 
less dependence on opioids for coping. 
Significance of the Study 
Opioid addiction can lead to death, criminality, numerous co-morbidities, re-
incarceration for previously incarcerated individuals, increased exposure to HIV and 
hepatitis C, and neonatal abstinence syndrome for newborns (NIDA, 2015). Those with 
PTS and a history of incarceration are at greater risk for these outcomes.  It is imperative 
to understand the relationship of PTS to MT to enable clinicians to intervene more 
appropriately and enhance treatment outcomes for those with co-occurring PTS and 
participating in MT.  Understanding how these interactions will also affect the recovery 
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process for those that have been incarcerated and will aid in long term success and 
adaptation. 
Viewing involvement in the criminal justice system through the lens of Lazarus 
and Folkman’s Transactional Stress theory, incarcerated men and women are already 
shown to be a greater risk when entering the system with a history of PTS.  As this PTS is 
exacerbated in an incarceration experience, it is hypothesized in this study, that PTS may 
moderate or strengthen the relationship between incarceration and successful OUD 
treatment outcomes.  Those with PTS and an incarceration history are at even greater risk 
for inappropriate appraisals of stress that could potentially become heightened after 
leaving prison or jail and entering OUD treatment.  Inaccurately appraising situations 
from a place of fear and trauma could result in the action to relapse and use substances 
once again. 
Developing a clearer understanding and framework for treatment within this 
subset of the population will allow clinicians to treat other groups of individuals suffering 
from the combination of PTS and OUD.  Veterans, sexual abuse survivors, refugees, or 
other individuals living with PTS and OUD will benefit from the approaches and 
practices that can be instituted as a result of the data gathered from this proposed study. 
Understanding these relationships more clearly will enable clinicians to intervene more 
appropriately when presented with someone with co-occurring PTSD and participating in 
MT.  Understanding how these interactions affect those with involvement in the criminal 
justice system who are in the process of recovery will aid in long term success.   
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CHAPTER 3 
METHODOLOGY 
Methods 
This chapter provides on overview of the research methodology that will be 
utilized in the proposed study.  The chapter ends with a conceptual definition of 
variables. 
Research Purpose 
The purpose of this study is to explore the relationships between post-traumatic 
stress (PTS), involvement in the criminal justice system (CJS), and medication treatment 
(MT) success in patients identified with an Opioid Use Disorder (OUD). 
Research Design 
This study will employ a correlational retrospective analysis of Electronic Health 
Records (EHR) data. 
Electronic Health Record / Retrospective Chart Review 
Since the inception of EHR, the ability to utilize these records beyond the scope 
of daily patient care and billing purposes has continued to merge into the field of research 
as a method to track all patient data for use either prospectively or accessed 
retrospectively.  The current utilization of EHR is commonly referred to as ‘clinical data 
reuse’ or ‘retrospective chart review’.  This reuse of data is employed in research realms 
such as: epidemiology, genomics, safety, clinical/treatment, and outcomes based research 
(Meystre et al., 2017). 
Advantages of the EHR Chart Review 
There are numerous advantages to EHR chart review.  A major benefit of chart 
reviews is that they are not as costly as experimental studies that require multiple staff, 
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locations, instruments, etc.  They are efficient uses of time as one can immediately derive 
data from a lengthy time period rather than conducting longitudinal experiments that may 
take years to conclude (Gearing, Mian, Barber, & Ickowicz, 2006).  Importantly, there 
may be instances in research when a researcher does not have the ability to randomize 
people for a variety of reasons.  EHR chart review is an especially poignant methodology 
in these cases (Worster & Haines, 2004). 
Disadvantages of the EHR Chart Review 
While the benefits of EHR chart review are substantial, there are drawbacks.  
Data itself needs to be input into a medical record. This initial input to the record itself 
can be suspect due to user error from the standing of the provider (Zozus et al., 2015).  
Data abstractors, or those who code and maintain the data, may not always be consistent 
and therefore increase the likelihood that data is retrieved in an inconsistent manner 
(Polnaszek et al., 2016; Vassar & Holzmann, 2013). Documenting research conducted 
using a chart review often does not include a thorough methodology that was utilized 
during data abstraction and analysis. 
Data Mining EHR 
EHR contain data that are either structured or unstructured.  This refers to the 
classification of data in a manner that is already accessible in a format that can be utilized 
immediately for research.  Unstructured data refers to data that is in an unclassified 
textual format (Meystre et al., 2017). 
Advantages of Data Mining 
Textual, unstructured data is often found in the form of written notes of 
physicians or clinicians, nurses, and other auxiliary care personnel.  Extracting this data 
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has the opportunity to provide useful data that may not be contained in the basic, 
formalized EHR. 
Disadvantages of Data Mining 
One major drawback to data mining is that clinicians are not typically charting 
everything that occurs or is witnessed in a visit.  Other times, some clinicians only chart 
by exception, meaning that only when the patient presents findings outside the normative 
expectations are they noted.  There are times when data is missing or contrary to other 
data within the EHR (Zozus et al., 2015). 
Setting and Sample 
Data was provided pertaining to patients receiving treatment at a multi-state, 
multi-site, office-based outpatient addiction treatment center that primarily provides 
medication treatment to patients with opioid use disorder.  Patients meeting criteria for an 
opioid abuse disorder according to the Diagnostic and Statistical Manual of Mental 
Disorders (Fifth edition) (APA, 2013) are permitted to receive treatment at the center. 
Upon admission, each patient undergoes a biopsychosocial assessment.  Following this 
assessment, an individualized treatment plan for each patient is developed. All sites 
within the treatment organization have access to and utilize an electronic health record 
(EHR) that provides robust monitoring.  This allows all physicians and nurse 
practitioners the ability to provide individualized care planning and management. 
Opioid use disorders are primarily treated with buprenorphine in an outpatient 
setting.  The treatment center employs evidence-based treatment for a range of substance 
use disorders (SUD), however most patient receive treatment for an opioid use disorder 
(OUD).  Given the focus of the study, only patients who received treatment for OUD will 
be included in analyses. As numerous changes have occurred at the protocol level within 
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the EHR, patients who received treatment between January 2016 and February 2018 will 
be included to provide the most consistent treatment protocol. Prior to analyses, patients 
under the age of 18 will be removed from the data file. This accounts for approximately 
1% of the patients treated at the treatment centers. 
Thus, in summary, inclusion criteria are patients who received treatment at an 
outpatient treatment facility who received OUD care between January 2016 and February 
2018 who received buprenorphine MT treatment. Exclusion criteria are patients who are 
under the age of 18. 
Sample Size 
An important aspect of planning a research study is determining the sample size.  
Ideally, the sample represents the population from which it is drawn so that findings can 
then be generalized to the target population (Kadam & Bhalerao, 2010).  The sample size 
depends on several elements:  the acceptable level of confidence, power of the study, 
expected effect size, underlying rate of the condition under study in the population, and 
standard deviation in a population (Kirby, Gebski, & Keech, 2002). 
Power Analysis 
Using G*Power 3.1.9.2, a power analysis was performed to estimate the required 
sample size. In the analyses, the following parameters were used: power = 0.80, alpha = 
0.05, and w = 0.1 (df=1). The effect size was based on a small effect size for contingency 
table goodness of fit test. Based on these parameters, a sample size of 785 is required for 
sufficient study power.  The database provided included data for 19,970 patients, thus 
there was ample power to complete this study. 
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Operational Definition of Variables 
The electronic health record (EHR) contains all the information that will be used 
in this study. A description of all study variables is provided below. 
Predictors 
There are four main predictor variables in this study: Post traumatic stress 
symptoms, a history of trauma, a history of involvement in the criminal justice system, 
and gender. All four of the predictor variables are dichotomous and nominal. 
Post-Traumatic Stress 
During patient intake, patients provide an extensive medical and social history.  
There are several locations in the EHR where data related to PTSD history could be 
entered by a provider.  Each of these fields is in free text format.  Each of these fields is 
in free text format.  After translating all text data to lower case, syntax was written to 
identify cases with a diagnosis of PTSD. The following phrases were identified in the text 
fields and flagged as trauma positive: ptsd and post-traumatic stress. In addition, a patient 
with any PTSD diagnosis code was identified as positive for PTSD. 
Trauma 
Similar to PTSD, during patient intake, patients provide an extensive medical and 
social history.  There are several locations in the EHR where data related to trauma 
history could be entered by a provider.  Each of these fields is in free text format.  Text 
from 500 was examined to identify provider specific phrases used to describe trauma in 
the EMR. After translating all text data to lower case, syntax was written to identify cases 
with evidence of a trauma history. 
The following phrases were identified in the text fields and flagged as trauma 
positive: stabbed, gunshot, traumatic, abused, hostage, victim of, rape, traumatic abuse, 
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childhood abuse, hx abuse, intimate partner violence, domestic violence, gun shot, bullet 
wound, trauma hx, physical abuse, sexual abuse, emotional abuse, assaulted, abuse as 
child, stab wounds, beat up, being shot, verbal abuse, bullet lodged, shrapnel, stab injury, 
sexually abused, physically abused, mugging, traumatic experiences, emotionally abuse, 
domestic violence, past sexual trauma, violent incident, abusive relationship, stabbing 
victim, molested, and kidnapped. In addition, a patient with a diagnosis code consistent 
with trauma was identified as positive for trauma. In addition, any patient identified as 
PTSD was also identified positive for trauma. 
Involvement in the Criminal Justice System 
The treatment provider evaluates patient involvement in the criminal justice 
system i.e. probation, awaiting trial, and past incarceration each quarter when the 
treatment plan is evaluated. This data is identified via check boxes. Providers are able to 
check either that there are “pending criminal charges” or “resolved criminal charges.”  If 
a patient is positive for either, they were identified as involved with the criminal justice 
system.  In addition, several patients were identified as having involvement in the 
criminal justice system through a separate database for patients who were part of a study 
performed by the treatment center location. All patients in the “Jail Database” were 
identified as positive for criminal justice system involvement. 
Gender 
Upon intake, during the patient’s history and physical exam, their gender is noted.  
This was recorded as either male or female. 
Dependent Variables 
Several dependent variables will be examined in this study including visit 
compliance, medication adherence, and drug use. 
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Treatment Compliance 
Patients that are more compliant with visits are considered to be progressing in 
treatment by facility treatment providers (Hser et al., 2015b; Kampman & Jarvis, 2015; 
Timko et al., 2016). There were several instances to assess visit compliance.  There are 
several types of encounters that are recorded in the EHR each time the patient is 
scheduled for a visit. These types of visits where an encounter is created include: 
provider visits, group visits, and random urine screen visits. Patients participate in group 
therapy treatment focused on OUD antecedents and consequences. These sessions are 
required as well as periodic random screening for opioid drug use. These encounters are 
recorded as “no-show” when the patient does not appear for their session. Tracking the 
number of times a patient does not come to a scheduled provider visit, a scheduled group 
visit, a random urine screen visit, and cancels group visits provide the opportunity to 
examine patient compliance. 
In the current proposal, the following variables were examined: the number of “no 
show visits”, number maintenance visits, number of initial visits, number of rejoin visits, 
number of induction visits, number of group visits, number of no show group visits, 
number of group cancellations, number of rescheduled visits, number of interruptions, 
and number of other encounters. In addition, the total time in case and the time since the 
last visit was evaluated. 
Patients with more than one initial visit or more than one induction visit, are 
having that visit because they had a period of stoppage in treatment. At the treatment 
facility, a patient is defined as not in treatment if they have not been seen by a provider 
within the past 30 days. The number of times a patient had more than 30 days outside of 
treatment was summed and labeled the number of care interruptions.  
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With the exception of the total time in care and the time since the last visit, all 
variables were adjusted based on total time in care, by dividing the variable by how long 
a patient had been in care.  
Medication Adherence  Since only patients treated with buprenorphine were 
included in this study, medication adherence was defined as buprenorphine positive. 
Urine screen data is available for every visit for each patient in the EHR. All 
buprenorphine urine screens were used to create the variable percent positive for 
buprenorphine. Positive screens were identified as “1”, while negative screens were 
identified as “0.” All were summed and divided by the total number of buprenorphine 
urine screens evaluated.  
Drug Use  
All drug use variables were obtained using the methodology described above. The 
drugs examined included opioids, benzodiazepines, alcohol, THC, amphetamines, 
cocaine, PCP, barbiturates, methamphetamines, and ecstasy. Percent positive for each of 
the drug categories was constructed. A composite opioid values was constructed from the 
following opioids: ultram, codeine, fentanyl, hydrocodone, hydromorphone, oxycodone, 
hepridine, morphine, heroin, oxymorphone, propoxyphrene, and methadone. In addition, 
there is a general opiate screen that was performed. At any visit a patient was identified 
as positive is any of the opioids listed were positive. Since there was minimal usage of  
PCP, barbiturates, methamphetamines, and ecstasy, these screens were summed as “other 
drugs.” 
Covariates 
In addition to the variables already presented, other variables that were available 
in the EHR were included in the analyses as covariates. These included age, race, 
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ethnicity, and treatment center location.  Since the sample is predominately white, a white 
yes/no variable was constructed and used in analyses. Similarly, since the majority of the 
patients were seen in Massachusetts, a Massachusetts yes/no variables was constructed 
and used in analyses. Finally, total time in care and time since the last visit were included 
as covariates when appropriate (i.e., when not the dependent variable).  
Measurement of Variables 
All variables were obtained from the EHR. The independent variables are nominal 
in scale. Dependent variables are ratio in scale. 
Procedures 
The treatment center will provide all data in individual CSV data tables. All data 
tables were imported into SPSS v25 and merged.  Files were merged based on patient 
MRN number. Prior to receiving the data, a study ID was created for each patient and a 
de-identified data file was used for analyses. IRB approval from the University of 
Massachusetts Amherst was received prior to data transfer. 
Data Analysis 
Prior to beginning study analyses, all variable distributions were evaluated for 
normality or data entry errors. Descriptive statistics were calculated for all variables.  
Analyses by study aim are described below. 
Aim 1. To compare outcomes of Medication treatment (MT) success in patients 
with elevated post-traumatic stress (PTS) and patients without PTS. 
Analyses to examine Aim 1 were performed using ANCOVA. All covariates were 
entered into the ANCOVA.  An ANCOVA was performed for each of the dependent 
variables. The independent variable PTSD was the between subjects variable. Gender 
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was also a between subjects variable and the interaction of PTSD and gender was 
examined. 
Aim 2: To compare outcomes of Medication treatment (MT) success in patients 
with elevated history of trauma (Trauma+) and patients without a history of trauma. 
Analyses to examine Aim 2 were performed using ANCOVA. All covariates were 
entered into the ANCOVA.  An ANCOVA was performed for each of the dependent 
variables. The independent variable trauma was the between subjects variable. Gender 
was also a between subjects variable and the interaction of trauma and gender was 
examined. 
Aim 3: To compare outcomes of Medication treatment (MT) success in patients 
with an history of involvement with the criminal justice system (CJS) and patients without 
a history of involvement in CJS. 
Analyses to examine Aim 3 were performed using ANCOVA. All covariates were 
entered into the ANCOVA.  An ANCOVA was performed for each of the dependent 
variables. The independent variable CJS involvement was the between subjects variable. 
Gender was also a between subjects variable and the interaction of CJS involvement and 
gender was examined. 
Aim 4. To examine if PTS status moderates the relationship between involvement 
in the criminal justice system and Medication Treatment success. 
Analyses to examine Aim 4 were performed using ANCOVA. All covariates were 
entered into the ANCOVA.  An ANCOVA was performed for each of the dependent 
variables. The independent variable PTS and CJS involvement were the between subjects 
variables. Gender was also a between subjects variable and the interaction of PTSD and 
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gender was examined.   Evidence of moderation was evaluated using the PTSD * CJS 
interaction term. 
Aim 5. To examine if trauma status moderates the relationship between 
involvement in the criminal justice system and Medication Treatment success. 
Analyses to examine Aim 5 were performed using ANCOVA. All covariates were 
entered into the ANCOVA.  An ANCOVA was performed for each of the dependent 
variables. The independent variable trauma status and CJS involvement were the between 
subjects variables. Gender was also a between subjects variable and the interaction of 
trauma and gender was examined.   Evidence of moderation was evaluated using the 
TRAUMA * CJS interaction term. 
Limitations 
Term Abstraction  
Term abstraction is identified as a potential limit to the study.  Term abstraction is 
the process in which terms related to PTS+ were identified and programmed for 
recognition by SPSS.  The terms themselves may be limiting and may not encompass all 
terms used by a provider or patient to identify a particular functional outcome. There is 
also the potential that some terms referring to functional outcomes may be used in the 
note written by the provider but not recognized due to their novelty.  
Protection of Human Subjects 
While the use of patient data should always be treated with the highest regard for 
confidentiality, using de-identified data within a secondary analysis will lessen the 
opportunity for breach of anonymity.  This study will follow criteria set forth by the 
University of Massachusetts Amherst Institutional Review Board and received board for 
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approval. All investigators completed the requisite training regarding the protection of 
human subjects to ensure that no harm comes to patients involved in this study.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
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CHAPTER 4 
RESULTS 
This chapter describes the results of the study.  It contains pertinent descriptive 
data used to identify the general characteristics of the study sample and covariates 
including: age, gender, ethnicity, state of treatment, race. The chapter also outlines the 
various levels of positive drugs screens throughout the sample.  This chapter also 
provides results based on the predictor variables (PTSD and History of Incarceration) and 
dependent variables (provider visit compliance, group visit compliance, random visit 
compliance, medication adherence, and illicit opioid use) utilized within various 
regression and mediation analyses as outline in the chapter 3. 
Sample  
The study sample consisted of 19,848 subjects ranging in age from 18-83 years 
with a mean age of 38.3 years (SD= 10.6). The majority of the sample was male at 57.8% 
and 69.9% white and received treatment within the state of Massachusetts (69.9%).  Just 
under 10% (9.5%) of the sample have a history of PTSD; while just over 10% a history of 
Trauma was noted in 12.0% of the sample. A total of 5115 (22.8%) subjects had an 
involvement in the criminal justice system (see Table 2). 
Table 2. Sample Characteristics (N=19,970). 
Socio-demographic Variables % 
Sex  
Male 57.3 
Race  
White 67.8 
Non-white 32.2 
Ethnicity   
Hispanic 12.7 
Non-Hispanic 87.3 
State of Treatment  
Massachusetts 69.9 
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All other states 30.1 
PTSD (% yes) 9.5 
Trauma (% yes) 12.0 
Criminal Justice Involvement (% yes) 22.8 
 
Relationship between Trauma, PTSD, CJS and Demographic Characteristics 
The relationship between PTSD, trauma history, and criminal justice status (CJS) 
was evaluated via chi-square (see Table 3).  Due to high study statistical power, a 
conservative alpha was used to evaluate statistical significance (α = 0.05). Gender was 
significantly related to PTSD, trauma, and CJS involvement.  More women were 
identified as having a history of PTSD (χ2 =211.0, p < 0.001) and trauma (χ2 = 234.7, p < 
0.001), while more men had a history of CJS (χ2 = 14.0, p < 0.001).  Ethnicity was not 
significantly related to PTSD status (χ2 = 0.009, p = 0.925) or CJS involvement (χ2 = 0.4, 
p = 0.542), but was significantly related to trauma status (χ2 = 18.5, p < 0.001). Hispanic 
patients had reported less trauma history that non-Hispanic patients. No significant 
relationships were found between race and PTSD (χ2 = 3.7, p < 0.054) or trauma (χ2 = 
2.1, p = .145).  White patients did report a significantly higher CJS (χ2 = 17.1, p < 0.001). 
As mentioned above, the majority of the patients were treated in Massachusetts (69.9%). 
Given the small number of patients treated in any of the other individual states, a 
dichotomous Massachusetts variable (treated in MA yes/no) was created and used in 
analyses. The state in which the subjects were treated showed significant proportions.  
Massachusetts has the largest proportion of subjects with PTSD at 11.6% (p < 0.001), 
trauma at 13.2% (p = 0.009) and CJS at 24.9 % (p < 0.001). 
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Table 3. PTSD/Trauma/CJS status and demographic characteristics. 
**p<.01. ***p<.001 
 
Relationship between Trauma, PTSD, CJS and Treatment Compliance 
The relationships between treatment visit compliance among PTSD, trauma 
history, and criminal justice status (CJS) was evaluated via independent sample t-tests 
(see Table 4) to evaluate for statistical significance. All relationships were significant for 
all three IV variables evaluated: PTSD (yes/no), Trauma history (yes/no), and CJS 
(yes/no).  Individuals who were positive for PTSD, trauma, or CJS had significantly more 
“no show” visits than without a trauma history (t’s = -12.6, -19.7, -30.7, all p’s < 0.001 
respectively).   Similarly, all risk groups for the three variables examined had more group 
cancellations (t’s = (-2.7, p = 0.007), (-5.5, p < 0.001), (-6.7, p < 0.0010 respectively), 
group “no show” visits (t’s = -7.4, -15.9, -21.0, all p’s < 0.001 respectively), and 
reschedules visits (t’s = -11.4, -19.6, -26.5, all p’s < 0.001 respectively).  All of these 
relationships suggest problems with treatment compliance which is supported by 
significantly more care interruptions for those with PTSD (t = -8.0, p < 0.001), trauma (t 
 PTSD Status Trauma Status CJS Status 
Variables No (n=17,876) 
Yes 
(n=1,945) χ
2 No (n= 17,278) 
Yes 
(n=2,543) χ
2 No (n=15,303) 
Yes 
(n=4,664) χ
2 
Sex  % %  % %  % %  
  Male  92.8 7.2 
211.0*** 
90.3 9.7 
234.7*** 
75.6 24.4 
14.0*** 
  Female 86.6 13.4 83.0 17.0 77.9 22.1 
Race           
  White  89.8 10.3 
3.7 
86.9 13.1 
2.1 
76.4 23.6 
17.1*** 
  Non-White 95.7 4.3 88.7 11.3 82.8 17.2 
Ethnicity           
  Hispanic   89.9 12.6 
0.0 
90.3 9.7 
18.5*** 
76.9 23.1 
0.4 
  Non-Hispanic  89.8 87.4 86.8 13.2 76.3 23.7 
State          
  
Massachusetts 88.4 11.6 150.4*** 
86.8 13.2 
6.8** 
75.1 24.9 
57.6*** 
  Other 94.0 6.0 88.1 11.9 79.9 20.1 
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= -5.8, p < 0.001) and positive CJS status (t = -17.7, p < 0.001). However, each of the 
risk groups for PTSD, Trauma, and CJS have significantly more maintenance visits (t’s = 
-13.1, -29.8, -37.2, all p’s < 0.001 respectively) and group visits (t’s = -8.4, -22.2, -26.7, 
all p’s < 0.001 respectively). At risk groups had been in care longer (t’s = -10.1, -25.2, -
31.5, all p’s < 0.001 respectively) and had been seen more recently (t’s = 5.1, 23.5, 12.8, 
all p’s < 0.001 respectively). These data suggest increased compliance. However, more 
initial visits (t’s = -16.7, -11.3, -22.1, all p’s < 0.001 respectively), more rejoin visits (t’s 
= -11.8, -13.5, -25.3, all p’s < 0.001 respectively), and more induction visits (t’s = -10.1, -
15.1, -25.5, all p’s < 0.001 respectively) for all three risk groups support care 
interruptions and lower treatment compliance.  Overall, the data suggest poorer treatment 
compliance for all three risk groups.  
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Table 4. Relationships between PTSD, Trauma, CJS, and Treatment Compliance. 
 
  PTSD Status  Trauma Status  CJS Status  
Treatment 
Compliance Total No Yes t No Yes t No Yes t 
  Mean Mean Mean  Mean Mean  Mean Mean  
# no show visits 3.3 3.2 4.8 -12.6*** 3.0 5.6 -19.7*** 2.6 5.5 -30.7*** 
Time since last visit 
(yrs.)  0.6 0.6 0.5 5.1
*** 0.6 0.3 23.5*** 0.6 0.5 12.8*** 
# maintenance visits 28.1 27.0 40.5 -13.1*** 24.5 54.1 -29.8*** 21.9 48.5 -37.2*** 
# initial visits 0.8 0.8 0.9 -16.7*** 0.8 0.9 -11.3*** 0.8 0.9 -22.1*** 
# rejoin visits 0.4 0.3 0.6 -11.8*** 0.3 0.6 -13.5*** 0.3 0.7 -25.3*** 
# induction visits 0.7 0.7 0.9 -10.1*** 0.7 0.9 -15.1*** 0.6 0.9 -25.5*** 
# group visits 1.3 1.2 1.7 -8.4*** 1.1 2.3 -22.2*** 1.0 2.0 -26.7*** 
# no show group 
visits 0.5 0.5 0.7 -7.4
*** 0.4 0.9 -15.9*** 0.4 0.9 -21.0*** 
# group cancellations   0.0 0.0 0.0 -2.7** 0.0 0.0 -5.5*** 0.0 0.0 -6.7*** 
# rescheduled visits 3.2 3.1 5.0 -11.4*** 2.8 6.0 -19.6*** 2.5 5.6 -26.5*** 
Total time in care  1.1 1.1 1.4 -10.1*** 1.0 1.9 -25.2*** 0.9 1.7 -31.5*** 
# of interruptions 0.8 0.8 1.0 -8.0*** 0.8 1.0 -5.8*** 0.7 1.1 -17.7*** 
# other encounters 25.6 24.4 37.7 -16.7*** 22.7 46.4 -31.2*** 19.9 41.3 -51.0*** 
**p<.01. ***p<.001 
 
Relationship between PTS, Trauma, & CJS and MT Adherence & Drug Use 
Medication Adherence 
The relationship between PTSD, trauma, and CJS and medication adherence was 
evaluated using independent t-tests (Table 5).  Mean percent positive buprenorphine 
screens were significantly higher for individuals positive for PTSD, trauma, or CJS (t’s = 
-6.4, -21.9, -21.8, all p’s < 0.001 respectively). These data show increased compliance for 
medication for all three at risk groups. These data do not support the hypothesis that 
individuals with trauma history, PTSD, or CJS are less compliant with MT. 
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Drug Use 
The relationship between PTSD, trauma, and CJS and drug use was evaluated 
using independent t-tests.  Those positive for PTSD, trauma, and CJS had significantly 
lower mean percent positive for opioid screens (t’s = 6.7, 16.5, 17.1, all p’s < 0.001) 
suggesting better outcomes for all three risk groups. However, all three risk groups had 
more positive amphetamine screens (t’s (-4.7, p < 0.001), (-6.9, p < 0.001), (-3.0, p = 
0.003 respectively). Individuals with PTSD had more cocaine screens (t = -4.0, p < .001) 
and alcohol use (t = 2.4, p < .016). None of the three risk groups had significantly more 
other drug use. There was less methadone use in patients with trauma and in patients 
positive for CJS. Finally, patients with PTSD and trauma had significantly more 
benzodiazepine screens (t’s = -11.2 and -6.3, both p’s < 0.001 respectively).  
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Table 5. Relationship between medication adherence and drug use by PTSD/Trauma/CJS  
 
 Total Sample 
PTSD 
Status  
Trauma 
Status  
CJS 
Status  
Drug (% 
positive)  No Yes t No Yes t No Yes t 
Buprenorphine 76.5  82.4 86.2 -6.4*** 81.4 90.9 -
21.9*** 
80.5 89.1 -
21.8*** 
Opiates † 15.3 16.0 13.2 6.7*** 16.5 11.0 16.5*** 17.1 12.1 17.1*** 
Amphetamines 5.5 5.6 7.6 -4.7*** 5.4 8.0 -6.9*** 5.6 6.4 -3.0** 
Cocaine 16.1 16.2 19.1 -4.0*** 16.7 15.7 1.8 16.3 17.2 -1.9 
THC 33.1 33.3 37.3 -4.1*** 33.7 34.3 -0.8 33.9 33.7 -0.2 
Alcohol 15.0 14.7 13.3 2.4 14.6 14.3 0.7 14.7 14.1 1.5 
Other †† 7.2 7.3 8.0 -0.6 7.1 8.6 -1.8 7.1 8.0 -1.2 
Methadone 2.2 2.2 2.0 1.1 2.3 1.6 3.9*** 2.5 1.3 9.0*** 
Benzodiazepines  9.3 8.7 13.8 -
11.2*** 
9.0 11.2 -6.3*** 9.3 9.3 -0.3 
**p<.01. ***p<.001 
† – Ultram, codeine, fentanyl, hydrocodone, hydromorphone, oxycodone, hepridine, 
morphine, heroin, oxymorphone, propoxyphrene.  
†† – PCP, barbiturates, methamphetamines, ecstasy.  
 
Summary 
In summary, patients who received treatment in Massachusetts, were white, non-
Hispanic.  Almost 25% of the sample had some involvement in the criminal justice 
system, 9.5% had PTSD, and 12% had a history of trauma.  Patients in each risk groups 
showed poorer treatment compliance with more “no show” provider and group visits and 
a higher number of overall encounters.  These risk groups also had a higher frequency of 
attendance to maintenance visits.  Patients with PTSD, trauma, and CJS had better 
medication adherence, but mixed results in drug screen results.  
Analysis of Study Aims 
AIM 1 –To compare outcomes of Medication treatment (MT) success in patients 
with elevated post-traumatic stress (PTS) and patients without PTS. 
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To examine the relationship between PTSD, Trauma, and CJS, several 
ANCOVAs were performed.  The between-subjects variable for all analyses were either 
PTSD history (yes/no), trauma history (yes/no), CJS involvement (yes/no) and gender 
(male/female).  Dependent variables included measures of treatment compliance, 
medication adherence, and drug use.  In addition to main effects, gender by PTSD, 
Trauma, or CJS interaction terms were evaluated. The covariates in the analyses included 
race, treatment state, age, ethnicity, total time in care, and time since last visit. For study 
aim analyses, a more conservative level of statistical significance was used (α = 0.01) due 
to high statistical power and the number of comparisons being evaluated. 
Relationship between PTSD and Treatment Compliance 
After including covariates, there were many significant differences in treatment 
compliance by PTSD history. Individuals with a history of PTSD had more “no shows” 
for maintenance visits (F(9, 12853) = 83.0, p<.001) than individuals without a history of 
PTSD, but there was no difference in frequency of “no shows” for group visits (F(9, 
12853) = 2.2, p= 0.155).  Individuals with PTSD had more initial visits, rejoin visits, 
inductions, and care interruptions (F(9, 12853) = 83.0, p<.001), (F(9, 12853) = 61.4, 
p<.001), (F(9, 12853) = 45.2, p<.001), (F(9, 12853) = 19.4, p<.001 respectively) than 
individuals without a history of PTSD. When an individual lapses from the program, as 
evidenced by increased care interruptions, and “rejoins” the program, they will have 
another initial visit and induction visit. Thus, there is evidence that individuals with 
PTSD have more care interruptions than individuals without a history of PTSD 
suggesting poorer treatment outcomes (see Table 6). 
Supporting data includes individuals with PTSD also had more total encounters 
(F(9, 12853) = 140.0, p<.001). After controlling for the amount of time in care and the 
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time since the last visit, staff interacted with patients with a history of PTSD more than 
individuals without a history of PTSD. Although individuals with a history of PTSD 
rescheduled their maintenance visit more frequently (F(9, 12853) = 24.0, p<.001), they 
also had more overall maintenance visits (F(9, 12853) = 36.0, p<.001).  Finally, there was 
also a significant relationship between PTSD status and total time in care (F(8, 12854) = 
20.3, p<.001) and the time since the last visit (F(7, 13369) = 23.5, p<.001). Patients with 
a history of PTSD were in care longer and had a shorter length of time since they were 
last seen.  
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Table 6. Relationship between Treatment Compliance and PTSD, Gender, and 
PTSD*Gender. 
 
 
†Time since last visit was not included as a covariate.  
††Total time in care was not included as a covariate.  
**p<0.01. ***p<0.001. 
 
Relationship between Gender and Treatment Compliance 
After including covariates, there were many significant differences in treatment 
compliance by Gender (see Table 7). Women had more “no show” maintenance visits 
(F(9, 12853) = 11.6 p = .001) and rescheduled their visits more frequently (F(9, 12853) = 
24.0, p<.001) than men. Women also had a statistically significant greater number of 
encounters (F(9, 12853) = 35.6, p <.001).  Women were also in care longer (F(9, 12854) 
= 28.1, p< .001). There were no significant PTSD by gender interactions.  
Treatment Compliance PTSD Gender PTSD X Gender 
 F F F 
# no show visits  45.1*** 11.6*** 0.4 
# initial visits  83.0*** 5.0 2.2 
# rejoin visits 61.4*** 0.4 0.8 
# induction visits 45.2*** 1.9 0.1 
# care interruptions  19.4*** 1.6 2.8 
# group cancellations   0.2 3.2 0.3 
# rescheduled visits 24.0*** 32.4*** 0.1 
# maintenance visits  36.0*** 0.5 0.1 
# other encounters 139.9*** 35.6*** 0.5 
# group visits 0.3 0.4 0.5 
# no show group visits 2.0 0.7 3.2 
Time since last visits (yrs) †  23.5*** 4.7 0.0 
Total time in care (yrs) †† 20.3*** 28.1*** 2.6 
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Relationship between Covariates and Treatment Compliance 
There were significant relationships between all covariates and at least some 
measures of treatment compliance (Table 8).  The race of the patient was related to 
induction visits (F(9, 12853) = 8.4, p = .004) and total time in care (F(9, 12853) = 16.5, p 
< .001). White patients had less induction visits than non-white patients.   Patients in 
Massachusetts had poorer compliance on the majority of the variables examined. For 
example, patients treated in Massachusetts were more likely to not attend scheduled 
maintenance visits (F(9, 12853) = 191.2, p < .001), and had more initial (F(9, 12853) = 
48.4, p < .001), rejoin (F(9, 12853) = 158.5, p < .001), and induction visits (F(9, 12853) 
= 95.8, p < .001).   However, Massachusetts patients had more total time in care (F(9, 
12853) = 1880.2, p < .001). 
Age was significantly related to treatment compliance measures. As patient’s age 
increased, the rate of “no show” visits (F(9, 12853) = 226.2, p < .001), rejoin visits (F(9, 
12853) = 42.8, p < .001), rescheduled visits (F(9, 12853) = 89.1, p < .001) and care 
interruptions (F(9, 12853) = 70.0, p < .001) decreased.  For patients, as age increased, 
groups visits (F(9, 12853) = 56.8, p < .001), encounters (F(9, 12853) = 129.6, p < .001), 
and total time in care (F(9, 12853) = 153.4, p < .001) increased. In regard to ethnicity, 
Hispanic patients were more likely to have more induction visits (F(9, 12853) = 16.2, p < 
.001) and attend maintenance visits (F(9, 12853) = 8.7, p = .003).  Non-Hispanic patients 
were more likely to attend group visits (F(9, 12853) = 26.7, p < .001). Total time in care 
was significantly related to all treatment compliance measures.  As the total time in care 
increased, so did the number of “no show” visits (F(9, 12853) = 1873.0, p < .001), 
maintenance visits (F(9, 12853) = 42048.3 p < .001), rejoin visits (F(9, 12853) = 
663.422, p < .001), induction visits (F(9, 12853) = 16.5, p < .001), groups visits (F(9, 
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12853) = 11563.8, p < .001), group “no show” visits (F(9, 12853) = 3429.0, p < .001), 
group cancelations (F(9, 12853) = 487.9, p < .001), encounters (F(9, 12853) = 11920.2, p 
< .001, and time since last seen.  In contrast, as total time in care increased, the number of 
initial visits (F(9, 12853) = 186.0, p < .001) and rescheduled visits (F(9, 12853) = 
3625.6, p < .001) decreased. As the time since last seen increased, total time in care (F(9, 
12854) = 1410.9, p < .001), attendance at maintenance visits (F(9, 11566) = 47.8, p < 
.001), and group visits (F(9, 12853) = 574.6, p < .001) decreased. 
Table 7. Relationship between Covariates and Treatment Compliance. 
 
Treatment Compliance Race Location Age Ethnicity Care Time Last Seen 
 F F F F F F 
# no show visits  5.7 191.2*** 226.3*** 5.6 1873.0*** 6.5 
# initial visits  0.4 48.4*** 0.4 2.9 186.0*** 397.8*** 
# rejoin visits 2.6 158.5*** 42.8*** 3.9 663.4*** 2.9 
# induction visits 8.4** 95.8*** 7.3** 16.2*** 16.5*** 59.7*** 
# care interruptions  0.0 172.5*** 70.0*** 4.1 329.0*** 91.8*** 
# group cancellations   0.1 1.1 0.1 0.2 487.9*** 5.1 
# rescheduled visits 1.8 116.4*** 89.1*** 0.2 3625.6*** 24.3*** 
# maintenance visits  0.8 28.0*** 0.1 8.7** 42048.3**
* 
270.4*** 
# other encounters 5.6 22.9*** 129.7*** 5.6 11920.2**
* 
99.9*** 
# group visits 3.8 37.4*** 56.8*** 26.7*** 11563.8**
* 
574.6*** 
# no show group visits 0.1 29.8*** 66.8*** 4.3 3429.0*** 69.3*** 
Time since last visits (yrs)  5.8 689.9*** 3.7 2.5 NA NA 
Total time in care (yrs)  36.2*
** 
1880.2**
* 
153.4*** 3.6 NA 1411.0**
* **p<.01. ***p<.001  
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MT Adherence and Drug Use within PTSD  
Medication Adherence 
The relationship between PTSD, medication adherence, and drug use was 
evaluated using ANCOVA (Table 9).  The PTSD group demonstrated greater medication 
adherence than the non-PTSD group. Consistent with the bivariate analyses, after 
controlling for covariates, patients with PTSD had a significantly greater number of 
positive buprenorphine screens than patients without PTSD (F(9, 11599) = 17.7, p < 
.001). 
Drug Use 
Although more compliant with buprenorphine, patients with PTSD had 
significantly more benzodiazepine use (F(9, 11599) = 76.5, p < .001), THC use (F(9, 
11599) = 12.8, p < .001), amphetamine use (F(9, 11599) = 10.7, p = .001), cocaine use 
(F(9, 11599) = 18.0, p < .001), and opioid use (F(9, 11599) = 17.8, p < .001).  PTSD 
status was unrelated to alcohol, methadone, and other drug use.  
Gender 
Men with PTSD used alcohol more frequently than women with PTSD (F(9, 
11599) = 21.4, p < .001) as well as THC (F(9, 11566) = 35.6, p < .001). In contrast, 
women were more positive for benzodiazepines than men (F(9, 11599) = 19.7, p < .001).  
There were no significant PTSD by gender interactions.   
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Table 8. Relationship between Medication adherence/Drug Use and PTSD/Gender. 
 
Drugs (% positive) PTSD Gender PTSD X Gender 
 F F F 
Buprenorphine  17.7*** 0.4 0.2 
Benzodiazepine  76.5*** 19.7**
* 
0.0 
THC  12.8*** 35.6**
* 
1.1 
Amphetamine  10.7** 3.8 2.7 
Alcohol  4.0 21.4**
* 
0.2 
Cocaine  18.0*** 0.0 0.2 
Opioids All  17.8*** 0.1 0.1 
Methadone  0.4 0.2 0.1 
Other drug  2.8 1.1 1.4 
**p<.01. ***p<.001 
 
Relationship between Covariates and MT Adherence and Drug Use 
Medication Adherence 
There were significant relationships between co-variates and measures of 
medication adherence and drug use (Table 10).   Compliance with buprenorphine was 
predicted by race (F(9, 11599) = 44.1, p < .001) and treatment location (F(9, 11599) = 
30.2, p < .001). White patient buprenorphine screens were more positive than non-white 
patients, while screens for patients treated in Massachusetts were less often positive, 
suggesting less medication adherence. Non-Hispanic patients (F(9, 11599) = 7.6, p < 
.006), were more compliant with their buprenorphine than Hispanic patients.  The 
patients that spent more total time in care (F(9, 11599) = 861.5, p < .001) had more 
positive buprenorphine screens.  As patients’ time since last seen (F(9, 11566) = 296.4, p 
< .001) increased, their percentage of buprenorphine decreased.   
 76 
Drug Use 
Patients in Massachusetts used alcohol (F(9, 11566) = 47.8, p < .001), THC (F(9, 
11599) = 64.7, p < .001), cocaine (F(9, 11566) = 123.1, p < .001), and opioids (F(9, 
11566) = 30.1, p < .001) more frequently than patients in other states.  Patient race was 
not related to benzodiazepines, alcohol, methadone, and other drugs, but White patients 
were less likely to use THC (F(9, 11566) = 12.4, p < .001), cocaine (F(9, 11567) = 50.2, 
p < .001), and opioids (F(9, 11599) = 40.3, p < .001). In contrast, White patients used 
amphetamines (F(9, 11566) = 20.0, p < .001) more frequently. Although Hispanic 
patients were less likely to use benzodiazepines (F(9, 11567) = 21.0, p < .001),  alcohol 
(F(9, 12853) = 8.2, p = .004) and amphetamines (F(9, 11566) = 27.4, p < .001), Hispanic 
patients were more likely to use THC (F(9, 11566) = 5.2, p = .022), cocaine (F(9, 11567) 
= 13.1, p = .001) and opioids (F(9, 11599) = 16.2, p < .001). 
Age was significantly related to all medication adherence and drug use. As 
patient’s age increased, the percent positive for screens of alcohol (F(9, 11562) = 52.6, p 
< .001) benzodiazepines (F(9, 11567) = 106.6, p < .001), and methadone (F(9, 11582) = 
18.5, p < .001) increased.   As the age of the patient increased, the percent positive screen 
of opioids (F(9, 11599) = 41.5, p < .001) decreased. Total time in care was related 
significantly to medication adherence (F(9, 11599) = 861.5, p < .001) with an increase in 
buprenorphine use.  As patients spent more time in care, the positive percent of 
buprenorphine increased.  As the total time in care increased, alcohol (F(9, 11567) = 
16.8, p < .001), cocaine (F(9, 11567) = 374.5, p < .001), methadone (F(9, 11582) = 84.1, 
p < .001), opioids (F(9, 11567) = 1065.2, p < .001), other drugs (F(9, 2441) = 4.1, p < 
.027) all decreased in positive screens. As total time in care increased, amphetamines 
(F(9, 11566) = 11.7, p = .001) and THC (F(9, 11566) =4.5, p < .034) increased in 
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positive screens.  Time since last seen was significantly related to all medication 
adherence and some drug measures.  As the time since last seen increased, positive 
buprenorphine (F(9, 11599) = 296.4, p < .001) screens decreased.  As time since last seen 
increased, the use of benzodiazepines (F(9, 11567) = 64.3, p < .001), alcohol (F(9, 
11562) = 9.126, p < .003), methadone (F(9, 11582) = 19.5 p < .001), and opioids (F(9, 
11599) = 407.9, p < .001) all increased. 
Table 9. Relationship between Medication adherence/Drug Use results and covariates 
 
Drugs (% 
positive) Race Location Age Ethnicity Care Time Last Seen 
 F F F F F F 
Buprenorphine  44.1*** 30.2*** 3.4 7.6** 861.5*** 296.4*** 
Benzodiazepine  4.8 0.5 106.6*** 20.9*** 0.2 64.3*** 
Alcohol  0.3 47.8*** 52.6*** 8.2** 16.8*** 9.1** 
THC  12.3*** 64.7*** 367.0*** 5.2* 4.5 0.0 
Amphetamine  20.0*** 56.2*** 3.3 27.4*** 11.7** 3.3 
Cocaine  50.2*** 123.1*** 3.5 13.1*** 374.5*** 1.4 
Methadone  0.5 0.6 18.5*** 3.6 84.1*** 19.5*** 
Other drug  2.3 740.4*** 0.6 0.1 4.9 0.5 
Opioids All  40.3*** 30.1*** 41.5*** 16.2*** 1065.2*** 408.0*** 
**p<.01. ***p<.001 
 
Summary of PTSD Results 
  Patients with a history of PTSD spent more time in care and attended more 
individual and group visits.   These patients had difficulty attending their scheduled 
meetings, had more initial visits as well as induction visits, and had a larger total number 
of other encounters.  While these patients utilized opioids, benzodiazepines, and THC 
more than those without PTSD, they were also more compliant with their medication 
adherence in the form of buprenorphine.   
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AIM 2 – To compare outcomes of Medication treatment (MT) success in patients 
with elevated and patients without PTS. 
Relationship between Trauma and Treatment Compliance 
After including covariates, there were many significant differences in treatment 
compliance by trauma history. Individuals with a history of trauma had more “no shows” 
for maintenance visits (F(9, 12853) = 116.6, p < .001) than individuals without a history 
of trauma, but there was no difference in frequency of “no shows” in group visits (F(9, 
12853) = 2.0, p= 0.157).  Individuals with trauma had more initial visits (F(9, 12853) = 
33.7, p < .001), rejoin visits (F(9, 12853) = 57.6, p < .001), inductions (F(9, 12853) = 
106.1, p < .001), and care interruptions (F(9, 12853) = 8.3, p = .004) than individuals 
without a history of trauma. Those with a history of trauma also rescheduled their 
maintenance visits more frequently (F(9, 12853) = 47.5, p < .001).  There is evidence that 
individuals with trauma had poorer treatment compliance outcomes than individuals 
without a history of trauma (see Table 11). 
Analyses not consistent with poorer treatment compliance include individuals 
with a history of trauma had more maintenance visits (F(9, 12853) = 132.0, p < .001) 
more other encounters (F(9, 12853) = 265.3, p = .000), total time in care (F(9, 12853) = 
420.8, p < .001), and had been seen more recently (F(9, 12853) = 274.7, p<.001).  
Gender and Treatment Compliance 
After including covariates, there were significant differences in treatment 
compliance by gender. Women had more “no show” visits for individual maintenance 
visits (F(9, 12853) = 50.2, p < .001) and group visits (F(9, 12853) = 9.3, p = .002) than 
men. In addition, women rescheduled more than men (F(9, 12853) = 91.0, p < .001) had 
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more total overall encounters (F(9, 12853) = 117.1, p<.001) and were in care longer than 
men (F(9, 12854) = 24.2, p< .001).  
Table 10. Relationship between Trauma, Gender, and Treatment Compliance. 
 
Treatment Compliance Trauma Gender Trauma X Gender 
 F F F 
# no show visits  116.6*** 50.2*** 31.4*** 
# initial visits  33.7*** 2.7 1.0 
# rejoin visits 57.6*** 1.3 0.2 
# induction visits 106.1*** 2.3 0.0 
# care interruptions  8.3** 3.9 1.1 
# group cancellations   0.6 4.5 0.7 
# rescheduled visits 47.5*** 91.1*** 17.2*** 
# maintenance visits  132.0*** 0.4 0.4 
# other encounters 265.3*** 117.1*** 46.8*** 
# group visits 0.1 1.9 3.5 
# no show group visits 2.0 9.3** 0.5 
Time since last visits (yrs)  274.7*** 2.8 0.1 
Total time in care (yrs)  420.8*** 24.3*** 4.1 
**p<.01. ***p<.001 
 
When examining the impact gender on the relationship between trauma and 
treatment compliance, three significant interactions were identified (see Table X). There 
was a significant interaction between trauma and gender and the number of “no show” 
visits (F(9, 12853) = 31.4, p < .001). For individuals without trauma, there was not a 
difference in “no show” visits by gender. In contrast, among those with PTSD, women 
had a higher number of “no show” visits then men (see Figure 3).    
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Figure 3. Trauma X Gender Interaction within “No Show” Visits.  
 
There was also a significant interaction between trauma and gender on the number 
of rescheduled visits (F(9, 12853) = 17.2, p < .001).  Similar to the number of “no show” 
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Women with PTSD had more rescheduled visits than women without PTSD (see Figure 
4).  
 
 
Figure 4. Trauma X Gender Interaction within Rescheduled Visits. 
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Finally, there was a significant interaction between trauma and gender and the 
number of total number of encounters (F(9, 12853) = 46.8, p < .001).  Men and women 
without a history of trauma had a similar number of encounters.  For those with a trauma 
history, women had more overall encounters than men (see Figure 5).  
 
 
Figure 5. Trauma X Gender Interaction and Number of Encounters.  
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There were significant relationships between covariates and several measures of 
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(F(9, 12853) = 34.6, p < .001).  Non-whites were more likely to have more induction 
visits and less total time in care.  Hispanic patients were significantly less likely to have 
“no show” maintenance visits (F(9, 12853) = 6.8, p = .009), attended more group visits 
(F(9, 12853) = 26.7, p < .001), and had more induction visits (F(9, 12853) = 18.6, p < 
.001).  Hispanic patients also had a significantly higher rate of maintenance visits (F(9, 
12853) = 10.3, p = .001).  
Age was significantly related to compliance measures such as attending “no 
shows” to maintenance visits (F(9, 12853) = 231.5, p < .001), rejoin visits F(9, 12854) = 
43.561, p < .001), encounters F(9, 12853) = 135.0, p < .001), and total time in care F(9, 
12853) = 142.7, p < .001). With the exception of induction visits, total time in care was 
significantly related to all treatment compliance measures. As the total time in care 
increased, the number of no shows (F(9, 12853) = 1674.6, p < .001), maintenance visits 
(F(9, 12853) = 40303.6 p < .001), rejoin visits (F(9, 12853) = 590.4, p < .001), induction 
visits (F(9, 12853) = 49.9, p < .001), groups visits (F(9, 12853) = 11208.0, p < .001), 
group no shows (F(9, 12853) = 3292.1, p < .001), group cancels (F(9, 12853) = 466.8, p 
< .001), encounters (F(9, 12853) = 11144.5, p < .001, and time since last seen (F(9, 
12853) = 1227.5, p < .001 all increased.  The number of initial visits (F(9, 12853) = 
197.9, p < .001) and rescheduled visits (F(9, 12853) = 3384.2, p < .001), decreased with 
the more time spent in care. As the time since patients were last seen increased the total 
time in care (F(9, 12854) = 1227.5, p < .001), maintenance visits F(9, 12853) = 246.0, p 
< .001) and group visits F(9, 12853) = 570.2, p < .001) all decreased.   
Table 11. Relationship between Treatment Compliance and Covariates.  
 
Treatment Compliance Race Location Age Ethnicity Care Time Last Seen 
 F F F F F F 
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# no show visits  5.8 222.7*** 231.5*** 6.8** 1674.3*** 3.3 
# initial visits  0.4 60.6*** 0.4 3.7 197.9*** 385.0*** 
# rejoin visits 2.5 181.8*** 43.6*** 4.9 590.4*** 4.5 
# induction visits 8.5** 113.8*** 7.8** 18.4*** 5.8 49.9*** 
# care interruptions  0.0 186.2*** 70.4*** 4.6 306.2*** 93.6*** 
# group cancellations   0.1 1.3 0.2 0.2 466.8*** 5.3 
# rescheduled visits 1.9 132.7*** 90.5*** 0.1 3384.2*** 20.0*** 
# maintenance visits  0.8 38.1*** 0.0 10.3** 40303.6*** 246.0*** 
# other encounters 5.7 41.5*** 135.0*** 4.0 11144.5*** 80.8*** 
# group visits 3.8 36.9*** 56.6*** 26.7*** 11208.0*** 570.2*** 
# no show group visits 0.1 31.4*** 66.7*** 4.1 3292.1*** 67.5*** 
Time since last visit (yrs)  6.6 694.1*** 2.1 3.6 NA NA 
Total time in care (yrs)  34.6*** 1936.0*** 142.7*** 2.4 NA 1227.5*** 
**p<.01. ***p<.001 
 
 
Relationship between Trauma, MT Adherence, and Drug Use  
Trauma, medication adherence, and drug use were evaluated using ANCOVA 
(table 13).  The trauma group demonstrated greater medication adherence than the non-
trauma group.  Consistent with the bivariate analyses, after controlling for covariates, 
patients with a history of trauma had a significantly greater number of buprenorphine 
positive screens than patients without a history of trauma (F(9, 12853) = 24.3, p <.001).  
Drug Use 
Although more compliant with their medication, those with a trauma history 
demonstrated significantly increased use of benzodiazepines (F(9, 12853) = 21.3, p < 
.001), amphetamines (F(9, 12853) = 18.1, p < .001) and cocaine (F(9, 12853) = 18.5, p < 
.001).  Unlike the PTSD group, the trauma and non-trauma group did not demonstrate a 
significant difference in their use of opioids (F(9, 12853) = 2.0, p = .165).   
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Gender 
Men had higher rates of drug use for the majority of the drugs tested. Men used 
more alcohol (F(9, 12853) = 18.096, p < .001), other drugs (F(9, 12853) = 4.107, p = 
.043), THC (F(9, 11566) = 54.9, p < .001), and amphetamines (F(9, 11566) = 14.9, p < 
.001) than women. In contrast, women used benzodiazepines significantly more than men 
(F(9, 11599) = 19.7, p = .000). There were no trauma by gender interactions related to 
medication adherence or drug use.  
Table 12. Relationship between Trauma, Gender, Medication adherence and Drug Use. 
Drug (% Positive) Trauma Gender Trauma X  Gender 
 F F F 
Buprenorphine 24.3*** 0.4 0.3 
Benzodiazepine 21.3*** 23.6*** 0.5 
Alcohol 0.2 18.1*** 1.1 
THC 1.7 54.9*** 0.0 
Amphetamine 18.1*** 14.9*** 0.3 
Cocaine 18.5*** 0.4 2.0 
Methadone 0.3 0.1 0.4 
Other drug 2.9 4.1 0.4 
Opioids All 1.9 1.1 0.1 
**p<.01. ***p<.001 
 
Relationship between Covariates and MT Adherence and Drug Use 
Medication adherence 
There were significant relationships between covariates and measures of 
medication adherence and drug use (Table 14).   Medication adherence was related to 
race (F(9, 11599) = 44.2, p < .001) with whites being more compliant, and treatment 
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location (F(9, 11599) = 25.0, p < .001) with those in Massachusetts less compliant.  In 
regard to ethnicity (F(9, 11599) = 6.9, p = .009), non-Hispanics were significantly more 
compliant. Age (F(9, 11599) = 3.3, p = .070) was not related to an increase in 
buprenorphine use.  Spending more time in care (F(9, 11599) = 798.1, p < .001) was 
related to an increase in buprenorphine use. A decrease in the time since last seen (F(9, 
11599) = 284.3, p < .001) were significantly related to increased buprenorphine use. 
Drug Use 
Patients in Massachusetts used more alcohol (F(9, 11562) = 46.3, p < .001), THC 
(F(9, 11566) = 70.6, p < .001), cocaine (F(9, 11567) = 136.1, p < .001), and opioids (F(9, 
11599) = 26.2, p < .001) more frequently than patients treated in other states. White 
patients were less likely to use THC (F(9, 11566) = 12.2, p < .001), cocaine (F(9, 11567) 
= 50.1, p < .001), and opioids (F(9, 11599) = 40.5, p < .001), but used amphetamines 
(F(9, 11566) = 20.0, p < .001) more frequently. Hispanic patients were significantly less 
likely to use benzodiazepines (F(9, 11567) = 19.1, p < .001),  alcohol (F(9, 11562) = 8.3, 
p = .004), and amphetamines (F(9, 11566) = 26.4, p < .001).  However, Hispanic patients 
were more likely to use THC (F(9, 11566) = 5.6, p = .018), cocaine (F(9, 11567) = 14.0, 
p < .001), and opioids (F(9, 11599) = 16.2, p < .001).  
Age was significantly related to medication adherence and most drug measures 
except amphetamine (F(9, 11566) = 3.4, p = .065), cocaine (F(9, 11567) = 3.7, p = .056) 
and other drugs (F(9, 11567) = 0.5, p = .474).  With the exception of benzodiazepines 
and amphetamines, an increase in total time care resulted in a decrease in alcohol F(9, 
11562) = 17.6, p < .001) , cocaine F(9, 11567) = 390.0, p < .001) , methadone F(9, 
11582) = 80.8, p < .001), other drugs F(9, 11599) = 6.2, p = .013) , and opioids F(9, 
11599) = 1025.6, p < .001).  The time since last seen was significantly related to 
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medication adherence and some drug use variables. As the time since last seen increased, 
patients decreased their use of buprenorphine (F(9, 11582) = 284.3, p < .001).   As the 
time since last seen increased, the percent of positive screens of benzodiazepine F(9, 
11567) = 67.7 p < .001), alcohol F(9, 11562) = 9.4 p < .001), methadone F(9, 11582) = 
19.4, p < .001), and opioids F(9, 11599) = 402.8, p < .001) all increased. 
Table 13. Relationship between Medication adherence, Drug Use, and Covariates.  
 
Drug (% 
Positive) Race Location Age Ethnicity Care Time Last Seen 
 F F F F F F 
Buprenorphine  44.2*** 25.0*** 3.3 6.9** 798.1*** 284.3*** 
Benzodiazepine  5.0 0.0 105.9*** 19.1*** 0.0 67.7*** 
Alcohol  0.3 46.3*** 52.4*** 8.3** 17.6*** 9.4** 
THC  12.2*** 70.6*** 366.7*** 5.6* 3.9* 0.0 
Amphetamine  19.9*** 50.4*** 3.4 26.4*** 7.3** 2.4 
Cocaine  50.1*** 136.2*** 3.7 14.0*** 390.0*** 2.1 
Methadone  0.5 0.5 18.5*** 3.5 80.8*** 19.1*** 
Other drug  2.3 726.5*** 0.5 0.2 6.2* 0.4 
Opioids  40.5*** 26.2*** 41.5*** 15.5*** 1025.6*** 402.8*** 
 **p<.01 ***p<.001 
 
AIM 3 – To compare outcomes of Medication treatment (MT) success in patients 
with an involvement in the Criminal Justice System (CJS) and patients without 
involvement in the CJS. 
 
Relationship between CJS and Treatment Compliance 
After including covariates, there were many significant differences in treatment 
compliance by CJS. Individuals with CJS had more “no shows” for maintenance visits 
(F(9, 12914) = 373.107, p<.001) than individuals without CJS.  Similarly, those with CJS 
had more “no show” group visits (F(9, 12914) = 24.720, p < 0.001).  Individuals with 
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CJS had more initial visits, rejoin visits, inductions, and care interruptions (F(9, 12914) = 
160.953, p<.001), (F(9, 12914) = 341.315, p<.001), (F(9, 12914) = 307.428, p<.001), 
(F(9, 12914) = 182.335, p<.001), respectively, than individuals without CJS. There is 
evidence that individuals with CJS have more care interruptions than individuals without 
CJS suggesting poorer treatment outcomes (see Table 15).  
Although there were no differences in the frequency in cancelling group visits, 
individuals with CJS did reschedule their visits more frequently (F(9, 12914) = 118.164, 
p<.001).  Individuals with a CJS also had more overall maintenance visits (F(9, 12914) = 
210.4, p<.001) and total other encounters (F(9, 12914) = 493.6, p<.001). Thus, even after 
controlling for the amount of time in care and the time since the last visit, staff are 
interacting with patients with a CJS more than individuals without CJS.  Finally, there 
was also a significant relationship between CJS and total time in care (F(8, 12914) = 
743.5, p<.001) and the time since the last visit (F(7, 13445) = 146.2, p<.001).  
Relationship between Gender and Treatment Compliance   
After including covariates, there were many significant differences in treatment 
compliance by Gender (Table 15). Women had more “no show” maintenance visits (F(9, 
12914) = 48.5, p < .001), rescheduled visits (F(9, 12914) = 104.6, p < .001), and had 
more group cancellations (F(9, 12914) = 10.6, p = .009) than men. Women had more 
encounters (F(9, 12914) = 136.7, p < .001) and were less likely to have interruptions in 
care (F(9, 12914) = 13.0, p < .001).  
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Table 14. Relationship between CJS, Gender, and Treatment Compliance. 
 
Treatment Compliance CJS Gender CJS X Gender 
 F F F 
 
# no show visits  373.1*** 48.5*** 7.9** 
# maintenance visits  210.4*** 3.4 0.0 
# initial visits  161.0*** 0.0 0.7 
# rejoin visits 341.3*** 1.7 3.2 
# induction visits 307.4*** 1.3 2.6 
# group visits 1.7 0.1 0.5 
# no show group visits 24.7*** 9.7** 0.5 
# group cancellations   1.7 10.6** 5.9 
# rescheduled visits 118.1*** 104.6*** 4.0 
# other encounters 493.6*** 136.7*** 16.1*** 
Time since last visits (yrs)  146.2*** 10.2** 0.6 
# care interruptions  182.3*** 13.0*** 3.5 
Total time in care (yrs)  743.5*** 68.7*** 6.6 
 **p<.01. ***p<.001 
 
There were two significant CJS by gender interactions: the number of “no show” visits 
and total encounters.  There was a difference in the relationship between CJS stats and 
frequency of no show maintenance visit between men and women (F(9, 12914) = 8.0,  p = 
.005)(Figure 6).  There was a larger difference between men and women in the number of 
no show visits for those with a history of involvement in CJS than for those without a 
history of CJS involvement. These data suggest that gender moderates the relationship 
between CJS and number of no shows.  
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Figure 6. Number of “No Shows” within CJS x Gender Interaction  
 
There was a difference in the number of encounters based on CJS history and 
gender (F(9, 12914) = 16.1, p < .001).  There was a larger difference between men and 
women in the number overall encounters for those with a history of involvement in CJS 
than for those without a history of CJS involvement (Figure 7). These data suggest that 
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Figure 7. Number of Encounters within CJS x Gender Interaction  
 
Relationship between Covariates and Treatment Compliance   
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.00) and total time in care (F(9, 12915) = 30.3, p < .001).  Non-whites were more likely 
to have more induction visits (F(9, 12915) = 9.5, p = .002) and less total time in care 
(F(9, 12915) = 30.3, p < .001).  Hispanic patients attended more group visits (F(9, 
12914) = 26.9, p < .001) and had more induction visits (F(9, 12914) = 17.0, p < .001).  
Hispanic patients also had a significantly higher rate of maintenance visits (F(9, 12914) 
= 9.6, p = .002).  
Age was significantly related to treatment compliance measures. As age 
increased, the number of  “no shows” to maintenance visits (F(9, 12914) = 57.8, p < 
.001) and the number of rejoin visits (F(9, 12914) = 22.0, p < .001), encounters (F(9, 
12914) = 86.2, p < .001) , rescheduled visits (F(9, 12914) = 69.4, p < .001) and 
interruptions in care (F(9, 12914) = 49.1, p < .001) decreased. As age increased, the total 
time in care (F(9, 12914) = 215.351, p < .001)  increased.  
With the exception of induction visits, the total time in care was significantly 
related to all treatment compliance measures.  As the total time in care increased, the 
number of no show visits (F(9, 12914) = 1503.3, p < .001),  rejoin visits (F(9, 12914) = 
465.3, p < .001), group no shows (F(9, 12914) = 3157.9, p < .001), group cancellations 
(F(9, 12914) = 455.1, p < .001), rescheduling (F(9, 12914) = 3232.0, p < .001), 
encounters (F(9, 12914) = 10743.0, p < .001), and interruptions (F(9, 12914) = 266.6, p < 
.001) increased.  However, maintenance visits (F(9, 12914) = 39510.2, p < .001) and 
groups visits (F(9, 12914) = 11008.4, p < .001) increased as well as total time in care 
increased.  As total time in care increased, the number of initial visits (F(9, 12914) = 
245.6, p < .001) and the time since last seen (F(9, 12914) = 1262.4, p < .001) decreased.   
As the time since last seen increased, the total time in care increases (F(9, 12915) = 
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1262.4, p < .001), while attending maintenance (F(9, 12914) = 263.5, p < .001) and group 
visits (F(9, 12914) = 570.0, p < .001) decreased.     
Table 15. Relationship between Treatment Compliance and Covariates.  
 
Treatment Compliance  Race Location Age Ethnicity Care Time Last Seen 
 F F F F F F 
# no show visits  7.2** 226.4*** 174.9*** 6.6 1503.3*** 4.4 
# maintenance visits  1.1 38.2*** 2.8 9.6** 39510.2*** 263.5*** 
# initial visits  0.3 66.1*** 3.2 3.8 245.6*** 385.3*** 
# rejoin visits 3.4 190.8*** 21.9*** 4.6 465.6*** 4.9 
# induction visits 9.5** 119.2*** 0.9 17.0*** 0.1 53.9*** 
# group visits 3.7 38.2*** 57.9*** 26.9*** 11008.4*** 570.0*** 
# no show group visits 0.2 32.0*** 57.8*** 4.2 3157.9*** 67.1*** 
# group cancellations   0.1 1.2 0.1 0.2 455.1*** 5.0 
# rescheduled visits 2.2 131.5*** 69.4*** 0.1 3232.0*** 22.2*** 
# other encounters 7.1** 40.4*** 86.2*** 4.6 10742.9*** 93.5*** 
Time since last visit (yrs)  7.5 727.3*** 7.5 2.9 NA NA 
# care interruptions  0.0 194.6*** 49.1*** 4.5 226.6*** 103.5*** 
Total time in care (yrs)  30.3*** 1899.0*** 215.5*** 3.0 NA 1262.4*** 
 **p<.01. ***p<.001 
 
Medication Adherence and Drug Use within CJS 
Medication Adherence 
 CJS, medication adherence, and drug use were evaluated using ANCOVA (Table 
17).  The CJS group demonstrated greater medication adherence that the non-CJS group.  
Consistent with bivariate analyses, after controlling for covariates, patients CJS had a 
significantly greater number of positive buprenorphine screens than patients without CJS 
(F(9, 11599) = 62.7, p < .001).  
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Drug Use 
 Although more compliant with their medication, patients with CJS had 
significantly more benzodiazepine use (F(9, 11567) = 43.4, p < .001), cocaine use (F(9, 
11567) = 34.3, p < .001) and other drug use (F(9, 2441) = 4.9, p = .028).  Those with CJS 
status used methadone (F(9, 11582) = 7.0, p = .008) and opioids (F(9, 11599) = 28.9, p < 
.001) less than those without CJS. CJS status was unrelated to THC, alcohol, and 
amphetamines,  
Gender   
There were several significant differences in drug use variables by gender. Men 
used significantly more THC (F(9, 11566) = 85.7, p = .000), alcohol (F(9, 11562) = 37.3, 
p < .001) and other drugs (F(9, 2441) = 4.0, p = .045) than women, but women used more 
amphetamines than men (F(9, 11566) = 21.1, p < .001).  There were no significant CJS 
by gender interactions.  
 
Table 16. Relationship between Medication adherence/Drug Use and CJS and Gender. 
 
Drugs (% Positive) CJS Gender CJS X Gender 
 F F F 
Buprenorphine  62.7*** 3.7 0.1 
Benzodiazepine  1.0 43.4*** 1.2 
Alcohol  0.0 37.3*** 0.0 
THC  6.4 85.7*** 0.1 
Amphetamine  2.8 21.1*** 0.2 
Cocaine  34.3*** 0.0 0.9 
Methadone  6.9 0.2 2.6 
Other drug  4.9 4.0 1.5 
Opioids All  28.9*** 2.1 0.0 
**p<.01. ***p<.001 
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Relationship between Covariates, MT adherence, and Drug Use 
Medication Adherence 
There were significant relationships between co-variates and measures of 
medication adherence and drug use (Table 18).   Medication adherence was related to 
race (F(9, 11599) = 43.1, p < .001) and treatment location (F(9, 11599) = 24.1, p < .001). 
Non-white and those treatment in Massachusetts were less compliant, while Hispanics 
were more compliant (F(9, 11599) = 7.1, p = .008). As Age (F(9, 11599) = 7.3, p = .007) 
and total time in care (F(9, 11599) = 738.2, p < .001) increases, the percentage of 
buprenorphine also increases.  As the time since last seen (F(9, 12914) = 296.0, p < .001) 
increased, the use of buprenorphine decreased.  
Drug Use 
Patients treated in Massachusetts use significantly more alcohol (F(9, 11562) = 
45.8, p < .001), THC (F(9, 11566) = 68.2, p < .001), cocaine (F(9, 11567) = 136.4, p < 
.001), amphetamine (F(9, 11566) = 52.4, p < .001) and opioids (F(9, 11599) = 24.9, p < 
.001) than patients treated in other states.  White patients were less likely to use THC 
(F(9, 11566) = 11.9, p = .001), cocaine (F(9, 11567) = 51.0, p < .001), and opioids (F(9, 
11599) = 39.7, p < .001), but used amphetamines (F(9, 11566) = 19.9, p < .001) more 
frequently than non-white patients. Hispanic patients were significantly less likely to use 
benzodiazepines (F(9, 11567) = 19.1, p < .001),  alcohol (F(9, 11562) = 8.3, p = .004), 
and amphetamines (F(9, 11566) = 26.4, p < .001).  Hispanic patients had a significantly 
higher use of cocaine (F(9, 11567) = 14.0, p < .001), and opioids (F(9, 11599) = 16.2, p < 
.001). Methadone, THC, and other drugs did not have a significant relationship with 
ethnicity.   
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Age was significantly related to medication adherence and most drug measures.  
Amphetamines (F(9, 11566) = 2.6, p = .111), cocaine (F(9, 11567) = 1.5, p = .223) and 
other drugs (F(9, 11567) = .4, p = .552) did not have a significant relationship to age.  
With the exception of benzodiazepines and other drugs, as total time in care increased, 
alcohol (F(9, 11562) = 16.6, p < .001) , cocaine (F(9, 11562) = 403.6, p < .001) , 
methadone (F(9, 11582) = 70.6, p < .001) and opioids (F(9, 11599) = 954.0, p < .001)  all 
decreased in positive screens. The time since last seen was significantly related to a 
decrease in medication adherence.  As the time since last seen increased (F(9, 11562) = 
16.6, p < .001) the percent positive of buprenorphine decreased.  As time since last seen 
increased, the percent positive screen of benzodiazepines (F(9, 11567) = 62.9, p < .001) , 
alcohol (F(9, 11562) = 9.2, p = .002) , methadone (F(9, 11582) = 19.1, p < .001) , and 
opioids (F(9, 11599) = 407.8, p < .001) increased.  
Table 17. Relationship between Medication adherence/Drug Use and Co-variates 
 
Drugs (% 
Positive) 
 
Race 
 
Location 
 
Age 
 
Ethnicity 
 
Care Time 
 
Last Seen 
 F F F F F F 
Buprenorphine  43.1*** 24.1*** 7.3** 7.1 738.2*** 296.0*** 
Benzodiazepin
e  
5.0 0.0 108.3*** 19.7*** 0.1 62.9*** 
Alcohol  0.3 45.8*** 52.1*** 8.3** 16.6*** 9.2** 
THC  11.9** 68.2*** 372.3*** 5.4 7.3** 0.0 
Amphetamine  19.9*** 52.4*** 2.5 26.9*** 9.2** 3.4 
Cocaine  51.0*** 136.4*** 1.5 13.7*** 403.6*** 1.4 
Methadone  0.5 0.4 15.8*** 3.5 70.6*** 19.1*** 
Other drug  2.3 736.7*** 0.3 0.2 6.3 0.6 
Opioids All  39.7*** 24.9*** 49.0*** 15.5*** 954.0*** 407.8*** 
**p<.01. ***p<.001 
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Summary of CJS Results  
 Patients with CJS status are spending more time in care, having more contact with 
care providers, and attending more individual maintenance visits.  These patients also had 
more difficulty attending their scheduled meetings, required more initial and inductions 
visits, had more rejoin visits, more encounters, and rescheduled more often than those 
without CJS.  Patients with a positive CJS status also complied more with medication 
treatment utilizing their prescribed buprenorphine more successfully than those without 
CJS.  This group also used opioids less than the non-CJS group but used more 
benzodiazepines and cocaine.   
Aim 4. To examine if PTS status moderates the relationship between involvement in 
the CJS and Medication Treatment success. 
 
To examine whether or not the interaction of PTSD or Trauma would moderate 
the relationship between involvement in the criminal justice system (CJS) and treatment 
success, a series of ANCOVA’s were completed. In these analyses, the impact of PTSD 
or Trauma, CJS, and the interaction term were examined.  Gender was also included as a 
between-subjects variable and included in the interactions examined. In addition to a 
discussion about significant interactions identified, only relationships between PTSD, 
trauma, or CJS and treatment compliance not already presented will be discussed below.  
For Aim 3 interactions, the traditional level of significance was used (α = 0.05).  
Treatment Compliance 
When evaluating the main effects of PTSD and CJS on treatment compliance in 
the analyses exploring potential interactions, all main effects were identical to analyses 
presented for Aims 1 and Aim 2. Analyses also identified several significant PTSD X 
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CJS interactions. The relationships in CJS groups were different for the levels of PTSD 
status for the number of initial visits, the number of induction visits, and time since the 
last visit (See Table 19).   
Table 18. Relationship between Treatment Compliance and PTSD, CJS, and Gender. 
 
Treatment Compliance PTSD CJS PTSD X CJS 
PTSD X 
Gender X CJS 
 F F F F 
# no show visits  27.2*** 158.4*** 0.1 0.2 
# maintenance visits  20.1*** 82.0*** 0.8 1.1 
# initial visits  36.5*** 21.8*** 26.3*** 1.8 
# rejoin visits 41.4*** 150.4*** 0.0 0.3 
# induction visits 15.0*** 78.7*** 16.7*** 3.2 
# group visits 1.5 0.1 2.8 1.0 
# no show group visits 1.5 14.9*** 0.4 0.5 
# group cancellations   0.8 3.1 1.8 1.2 
# rescheduled visits 19.1*** 66.7*** 1.5 1.3 
# other encounters 112.6*** 255.4*** 3.1 0.7 
Time since last visit (yrs)  8.1** 36.5*** 6.4** 1.6 
# care interruptions  11.4** 77.7*** 0.0 0.5 
Total time in care (yrs)  6.0* 306.7*** 0.3 0.6 
*p<.05 **p<.01 ***p<.001 
When examining for a potential moderating effect of PTSD on the relationship 
between CJS and the number of initial visits, there was a significant interaction (F(13, 
12849) = 26.3, p = 0.001). Among individuals without a history of CJS, there was a 
difference in the number of initial visits based on PTSD status.  For those with a history 
of CJS, there was no difference in the number of visits based on PTSD status. These data 
suggest that PTSD moderates the relationship between CJS and initial visits (See Figure 
8).   
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Figure 8. Initial visits by PTSD x CJS interaction. 
 
There was a significant interaction of PTSD X CJS on the number of induction 
visits (F(13, 12849) = 16.7, p < 0.001).  Regardless of PTSD history individuals with a 
history of CJS had more induction visits than those without a history of CJS history. 
Among those who did not have a history of CJS, patients with PTSD had a higher rate of 
induction visits than those without PTSD.  These data suggest that PTSD moderates the 
relationship between CJS and induction visits (see Figure 9).  
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Figure 9. Induction visits by PTSD x CJS interaction. 
 
The relationship between CJS and time since the last visit was different across the 
different PTSD groups [F(13, 13365) = 6.4, p = 0.011].  The difference in time since the 
last visit was greater between those who had PTSD and those who did not have PTSD 
among those without a history of CJS.  If there was a history of CJS, there was minimal 
difference in the time since the last visits.  These data suggest that PTSD moderates the 
relationship between CJS and time since last seen (see Figure 10).  
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Figure 10. Time since last visit by PTSD x CJS interaction. 
 
Impact of PTSD on the Relationship between CJS and MT/Drug Use 
Medication Adherence 
When evaluating the main effects of PTSD and CJS on medication adherence and 
drug use, the majority of the main effects were identical to what was presented in Aims 1 
and 2. However, there were a few exceptions: opioids, THC, and other drugs (see Table 
20).  The impact of CJS on opioid use was statistically significant in prior analyses. In the 
current analysis, the impact of CJS fell below the threshold for significance (F(13, 11595) 
= 3.7, p = 0.056). In contrast, although the impact of CJS on THC and other drugs was 
not significant in AIM 2 analyses, in the current analyses, individuals with a history of 
CJS had less THC use [F(13, 11595) = 4.2, p = 0.041] and more other drug use [F(13, 
11595) = 9.3, p = 0.002].  When examining for the potential of a CJS X PTSD interaction 
on medication adherence and drug use, the relationship between CJS and medication and 
opioids use were different across the PTSD levels. There were no significant PTSD X 
CJS X Gender interactions.  
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Table 19. Relationship of Medication adherence/Drug Use by PTSD, CJS, and Gender. 
  
 
*p<.05 **p<.01. ***p<.001 
 
There was a significant interaction of PTSD and CJS on the percent positive 
buprenorphine screens [F(13, 11595) = 6.2, p = 0.013]. Among individuals without a 
history of CJS, those with PTSD had the higher percentage of buprenorphine positive 
screens than those without PTSD (Figure 11). These data suggest that PTSD moderates 
the relationship between CJS and medication adherence.   
 
 
Drug (% Positive) PTSD CJS PTSD X CJS 
PTSD X Gender X 
CJS 
 F F F F 
Buprenorphine  7.2** 13.1*** 6.2* 1.2 
Benzodiazepine  65.3*** 0.2 0.0 1.9 
Alcohol  3.3 0.3 0.2 1.2 
THC  11.7** 4.2* 0.0 0.1 
Amphetamine  10.6** 2.2 0.5 0.2 
Cocaine  12.8*** 13.7*** 0.1 0.2 
Methadone  0.0 0.3 2.6 1.0 
Other drug  3.8 9.3** 4.8 0.8 
Opioids  8.7** 3.7 5.3* 0.0 
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Figure 11. The % positive for buprenorphine among PTSD x CJS interaction. 
 
Drug Use 
There was a significant difference in the relationship between CJS and opioid use 
based on PTSD status [F(13, 11595) = 5.3, p = 0.021](Figure 12).  There was minimal 
difference in the percentage of positive opioid screens for those with a CJS history.   
Among those without a history of CJS, those without PTSD had a higher percentage of 
positive opioid screens than those without PTSD.  These data suggest that PTSD 
moderates the relationship between CJS and percent positive of opioid screens.   
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Figure 12. The % positive for opioids by PTSD x CJS interaction. 
 
Aim 5. To examine if trauma status moderates the relationship between involvement 
in the CJS and Medication Treatment success. 
  
 Impact of Trauma on the Relationship between CJS and Treatment Compliance  
 
When evaluating the main effects of trauma and CJS among treatment compliance 
indicators, most of the main effects were as described in AIMS 1 and 2. The only 
exception was care interruptions. Although in AIM 1 there was a significant relationship 
between Trauma and care interruptions, in the current analyses, this relationship was no 
longer significant (F(13, 12849) = 2.0, p = .153)(See Table 21). When examining for CJS 
X trauma interactions, several were identified: “no show” visits, initial visits, induction 
visits, group visits, number of encounters, and time since the last visit.  There were also 
several trauma X CJS X gender interactions: “no show” visits, maintenance visits, and 
the total number of encounters.  
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Table 20. Relationship of Treatment Compliance by Trauma, CJS, and Gender 
 
Treatment Compliance Trauma CJS Trauma X CJS Trauma X CJS X Gender 
 F F F F 
# no show visits  19.2*** 277.5*** 17.9*** 5.3* 
# maintenance visits  106.6*** 105.6*** 0.0 11.0** 
# initial visits  7.6** 26.1*** 47.0*** 0.0 
# rejoin visits 36.7*** 201.7*** 0.3 1.3 
# induction visits 61.7*** 112.9*** 11.6** 2.7 
# group visits 0.7 1.8 13.3*** 0.0 
# no show group visits 1.9 22.1*** 2.2 0.2 
# group cancellations   1.3 3.6 2.5 0.3 
# rescheduled visits 41.5*** 81.3*** 3.5 0.6 
# other encounters 256.5*** 371.2***  28.4*** 9.1** 
Time since last visit (yrs)  163.7*** 19.0*** 29.3*** 0.1 
# care interruptions  2.0 88.8*** 1.4 0.0 
Total time in care (yrs)  314.1*** 399.9*** 2.4 0.8 
*p<.05 **p<.01. ***p<.001 
 
There was a difference in the relationship between CJS and the number of “no 
show” visits by trauma status (F(13, 12849) = 17.9, p < 0.001).  Patients with trauma and 
a history of CJS had a higher rate of ‘no show’ visits than patients without PTSD and a 
history of CJS (Figure 13). These data suggest that trauma moderates the relationship 
between CJS and “no show” visits.   
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Figure 13. Total # of no show visits within trauma x CJS  
 
 
 
Evaluation of the interaction of Trauma and CJS on the number induction visits, 
identified a significant effect (F(13, 12849) = 11.6, p < 0.001). Individuals with CJS had 
a high rate of encounters regardless of trauma history. In contrast, if there was not a 
history of involvement with CJS, individual with a trauma history had more induction 
visits, than those with a trauma history. These data suggest that trauma moderates the 
relationship between CJS and induction visits (see Figure 14).   
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Figure 14. Total # of induction visits within trauma x CJS. 
 
There was also a significant trauma X CJS interaction on the number of 
encounters (F(13, 12849) = 28.4, p < 0.001).  The relationship between CJS and the 
number of encounters was greater for those with a history of trauma than those without a 
history of trauma. These data suggest that Trauma moderates the relationship between 
CJS and the number of encounters (see Figure 15).   
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Figure 15. Total # of encounters within trauma x CJS. 
 
There was a difference in the relationship between CJS status and time since last 
visit (F(13, 12849) = 29.3, p < 0.001) based on trauma history group membership. If a 
patient had a history of trauma, time since a patient was last seen was virtually identical 
between CJS groups.  If a patient had a history of trauma, patients who also had a history 
of CJS had been seen more recently than individuals without a history of CJS.  These 
data suggest that trauma moderates the relationship between CJS and time since last seen 
(Figure 16).   
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Figure 16. Time since last visit by trauma x CJS interaction. 
 
There was a difference in the relationship between CJS status and initial visit 
(F(13, 12849) = 47.0, p < 0.001) based on trauma history group membership. For those 
with a trauma history, there is minimal difference in initial visits based on CJS status with 
those with a CJS status being slightly lower.  Among those without a trauma history, 
those with a history of CJS had more initial visits than patients without a history of CJS. 
These data suggest that trauma moderates the relationship between CJS and number of 
initial visits (Figure 17). 
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Figure 17. Total # of initial visits by trauma x CJS interaction. 
 
There was a difference in the relationship between CJS status and group visits 
(F(13, 12849) = 13.3, p < 0.001) based on trauma history group membership. For those 
with a trauma history, there is a difference in group visits based on CJS status with those 
with a CJS status being lower.  Among those without a trauma history, those with a 
history of CJS had more group visits than patients without a history of CJS. These data 
suggest that trauma moderates the relationship between CJS and number of group visits 
(Figure 18). 
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Figure 18. Total # of group visits by trauma x CJS interaction. 
 
Impact of Trauma on the Relationship between CJS and MT Adherence/Drug Use 
Medication Adherence 
When evaluating the main effects of trauma and CJS among medication 
adherence and drug use, all of the main effects were as described in AIMS 1 and 2. In 
addition, there was also a significant trauma X CJS interaction for buprenorphine and 
opioids (Table 22). There were no significant trauma X CJS X gender interactions.  
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Table 21. Relationship between Medication adherence/Drug Use by PTSD, CJS, and 
Gender. 
 
Drug (% Positive) Trauma CJS Trauma*CJS Trauma*CJS*Gender 
 F F F F 
Buprenorphine  9.8** 12.1** 15.6*** 0.0 
Benzodiazepine  22.5*** 1.7 1.7 0.1 
Alcohol  0.6 0.7 1.7 0.2 
THC  2.3 2.9 0.2 0.2 
Amphetamine  17.2*** 2.1 0.4 0.0 
Cocaine  17.2*** 24.5*** 1.4 1.3 
Methadone  0.0 2.4 0.6 0.1 
Other drug  2.9 4.4* 0.5 0.0 
Opioids All  0.0 4.8* 11.0** 1.5 
*p<.05 **p<.01. ***p<.001 
 
As mentioned, there was a significant impact of trauma on the relationship 
between CJS and medication adherence.  Regardless of CJS status, patients with a history 
of trauma had high rates of medication adherence (F(13, 11595) = 15.7, p < 0.001).  
Among those without a history of trauma, patients without a history of CJS had lower 
rates of medication adherence than patients without a history of CJS. These data suggest 
that trauma moderates the relationship between CJS and number of and percent of 
positive buprenorphine screens (Figure 19).   
 
 112 
 
Figure 19. The % positive for buprenorphine within CJS x Trauma interaction. 
 
Drug Use  
There is a significant difference between CJS and opioid use based on Trauma 
status (F(13, 11595) = 11.0, p = 0.001).  For those with a trauma history, there is minimal 
difference in opioid use based on CJS status.  Among those without a trauma history, 
those without a history of CJS had more opioid use than patients with a history of CJS. 
These data suggest that trauma moderates the relationship between CJS and number of 
encounters (Figure X).  These data suggest that trauma moderates the relationship 
between CJS and number of encounters (Figure 20).    
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Figure 20. The % positive for opioids by CJS x Trauma interaction.  
Influence of Gender on the Relationships between Trauma and CJS and Outcomes  
 Exploring the influence of gender on the relationships between trauma and CJS 
on outcomes did not identify many significant interactions.  Only the number of “no 
show” visits and the number of maintenance visits were significant.   There was a 
significant impact of gender on the interaction of trauma and CJS on maintenance visits 
[F(13, 12849) = 11.0, p = 0.001].   When examining the impact on trauma and CJS on the 
number of maintenance visits for men is different than for women. For men, those with a 
history of trauma have more maintenance visits regardless of CJS history (Figure 21).  
For women, the impact of CJS history appears to have more of an impact on the overall 
number of maintenance visits attended (Figure 22). These data suggest that gender 
moderates the relationships between trauma, CJS, and maintenance visits.  
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Figure 21. Maintenance visits by CJS and Trauma for Men.   
 
 
 
 
Figure 22. Maintenance visits by CJS and Trauma for Women.  
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Figure 23 and 24 presents the data for the number of “no show” visits by trauma 
and CJS history by gender. There was a significant interaction of gender, trauma, and 
CJS status for the number of “no show” visits (F(13, 12849) = 5.3, p = 0.021).  There was 
minimal different in the number of “no show” visits based on trauma history for men.  
Both trauma groups had more “no show” visits if there was a history of involvement with 
CJS than if there was no history of CJS.  For women, there were minimal differences 
among those without trauma based on CJS status.  If there was a history and CJS and 
there was also a history of trauma, there was a high rate of “no show” visits.   These data 
suggest that gender moderates the relationships between trauma, CJS, and “no show” 
visits. 
 
 
 
 
Figure 23. “No show” visits by CJS and Trauma for Women.   
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Figure 24.  Figure X. “No show” visits by CJS and Trauma for Men.   
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CHAPTER 5 
DISCUSSION 
This chapter provides a discussion of the findings of the study.  This study set out 
to understand the impact that post-traumatic stress (PTS), trauma, and an involvement in 
the criminal justice system has on the outcomes of opioid use disorder treatment.  This 
study utilized treatment compliance outcomes, medication adherence outcomes, and drug 
use as the findings This study sought to answer three major questions:  
1. Do those patients with PTSD has less successful treatment outcomes than 
those without PTSD?  
2. Do those patients with an involvement in the criminal justice system have less 
successful treatment outcomes than those without an involvement in the 
criminal justice system?  
3. Does PTSD/Trauma moderate the relationship between the having a criminal 
justice status and treatment outcomes?  
Summary of Results 
Table 23 provides a summary of the relationships between each of the 
independent variables (PTSD, trauma, criminal justice status, and gender) among both the 
treatment/medication adherence indicators and drug use indicators.  Table 24 provides a 
summary of the results from interaction analyses between all treatment compliance 
indicators and drug use by independent variables by gender and CJS.   
 
 
 
 
 
 118 
Table 22. Summary of relationships by Treatment compliance and Drug Use 
 
Treatment 
Compliance PTSD Trauma CJS Gender 
# no show visits  + + + + (W­) 
# initial visits  + + + - 
# rejoin visits + + + - 
# induction visits + + + - 
# care interruptions  + + + + (M­) (CJS) 
# group cancellations   - - - + (W­) (CJS) 
# rescheduled visits + + + + (W­) 
# maintenance visits  + + + - 
# other encounters + + + + (W­) 
# group visits - - - - 
# no show group visits - - + + (W­) (Trauma/CJS) 
Time since last visits (yrs)  + + + + (M­) (CJS) 
Total time in care (yrs)  + + + + (W­) 
Medication/Drug Use PTSD Trauma CJS Gender 
Buprenorphine  + + + -  
Benzodiazepine  + + - + (W­) 
THC  + - - + (M­) 
Amphetamine  + + - + (W­) (Trauma/ CJS) 
Alcohol  - - - + (M­) 
Cocaine  + + + -  
Opioids All  + - - - 
Methadone  - - - - 
Other drug  - - - - 
+ = a relationship between treatment compliance or drug use and IV’s  
- = no support of a relationship between DV and IV  
Unless otherwise noted, +/- apply to all PTSD, Trauma, and CJS groups 
M = men, W = women,  
­ = highest #/percent 
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Table 23. Summary of interactions by Treatment/ compliance and Drug Use 
 
Treatment 
Compliance PTSD x CJS 
Trauma 
x CJS 
PTSD 
x 
Gender 
Trauma 
x 
Gender 
CJS x 
Gender 
PTSD x 
Gender 
x CJS 
Trauma x 
Gender x 
CJS 
# no show visits  - + - + (W­)  + (W­) - + (M­ w/CJS) 
(W­ w/CJS) 
# initial visits  + - - - - - - 
# rejoin visits - - - - - - - 
# induction visits + + - - - - - 
# care interruptions  - - - - - - - 
# group cancellations   - - - - - - - 
# rescheduled visits - - - + (W­)  - - - 
# maintenance visits  - - - - - - + (M­/Trauma) 
(W­ w/CJS) 
# other encounters - + - + (W­)  + (W­) - + (M­ w/CJS) (W­ w/CJS) 
# group visits - - - - - - - 
# no show group 
visits 
- - - - - - - 
Time since last visits 
(yrs)  
- + - - - - - 
Total time in care 
(yrs)  
- - - - - - - 
Medication/Drug 
Use 
PTSD 
x CJS 
Trauma 
x CJS 
PTSD 
x 
Gender 
Trauma 
x 
Gender 
CJS x 
Gender 
PTSD x 
Gender 
X CJS 
Trauma x 
Gender X 
CJS 
Buprenorphine  + + - - - - - 
Benzodiazepine  - - - - - - - 
THC  - - - - - - - 
Amphetamine  - - - - - - - 
Alcohol  - - - - - - - 
Cocaine  - - - - - - - 
Opioids All  + + - - - - - 
Methadone  - - - - - - - 
Other drug  + - - - - - - 
+ = a relationship between treatment compliance or drug use and IV’s  
- = no support of a relationship between DV and IV  
Unless otherwise noted, +/- apply to all PTSD, Trauma, and CJS groups 
M = men, W = women, ­ = highest #/percent 
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The Impact of PTSD on Treatment Compliance 
 Patients with a positive PTSD status were not as successful in meeting treatment 
compliance indicators as those without PTSD.  It was hypothesized that those patients 
with PTSD would have a lower rate of attending scheduled individual and group visits.   
Furthermore, it was thought that these patients would not attend meetings without 
notifying center staff, that they would reschedule and cancel group visits more often, 
have more encounters with staff, leave care more often and need more initial, inductions, 
and rejoin visits.  Those patients with an increase in PTSD symptoms did reveal less 
treatment compliance throughout many treatment indicators and increased drug use.  It 
was hypothesized that those patients with PTSD would have a lower rate of adherence to 
buprenorphine and an increase in other drug use, especially opioid use.  There is more 
than adequate evidence demonstrating that buprenorphine treatment contributes to higher 
retention in treatment, lower opioid use, lower other substance use, and lower mortality 
(D’Onofrio et al., 2017; Mattick, Breen, Kimber, & Davoli, 2014; Parks Thomas et al., 
2014). Yet, despite this evidence, these findings are not evident when considering 
evidence of PTSD or a history of trauma.  Patients within this study with PTSD are more 
buprenorphine adherent than those without PTSD yet are also having higher percentages 
of opioid and other substance use and failing to meet treatment compliance indicators 
highlights the major issue these patients are struggling to stay med compliant and their 
immediate needs are not being met.  
 Patients with PTSD did not appear for scheduled individual visits more frequently 
than those without PTSD.  It has been noted previously that treatment for co-occurring 
SUD/PTSD has the potential for high drop-out rates and a reduction in treatment due to 
the stress of reliving traumatic events (Gielen, Krumeich, Havermans, Smeets, & Jansen, 
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2014; Kehle-Forbes et al., 2016).  The differences in practitioner’s ability to effectively 
counsel based on an integrated therapy for both SUD/PTSD may also contribute to some 
patients feeling not fully supported (Killeen, Back, & Brady, 2015) and thus not attend 
scheduled individual meetings.  Surprisingly, there were no differences noted with 
regards to any of the group visit indicators.   The number of group visits cancellations, 
the amount of ‘no show’ visits, and the number of group visits overall did not 
significantly differ from those without PTSD.  This may be that those feel more 
supported by peer-oriented groups.  There is the additional motivation for patients to 
remain compliant with group visits as this is required for them to be prescribed MT by 
clinicians.    
 Unexpectedly, those with PTSD attended more maintenance visits than those 
without PTSD.  This may be attributed again to either a higher gestalt rating from the 
provider and needing a greater degree of follow-up as well as a desired coping 
mechanism to continue medication treatment.  Though their results are based on a 
considerably smaller sample size than this study, this outcome is contrary to Norman, 
Tate, Wilkins, Cummins, & Brown (2010).  They determined that there were no 
differences between those with and without PTSD and their attendance at maintenance 
visits.   
 It was expected that those patients with PTSD would have a shorter time since last 
seen and have a longer duration in care.  It was found that these patients have a shorter 
time since last seen. Since patients are having more encounters with staff, their time 
between visits should be shorter and indicative of increased risk for relapse.  It is possible 
that the clinical staff (advance practice nurses and physicians) placed them on a higher 
level of intervention which would result in more frequent visitation.  One can view this as 
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potentially beneficial for them as it does allow them the opportunity to seek help and 
interact with staff more frequently.  
 The patient’s total time in care increases with PTSD.   As this is cumulative time 
in treatment, when accounting for the fact that those with PTSD have an increased 
number of initial visits, rejoins, inductions, interruptions, and reschedules, this has the 
potential to add a significant amount of time to their overall treatment.  The significant 
need for long term treatment for those with co-occurring PTSD and OUD has been noted 
by Mills et al. (2018) at 11-years follow-up, 46% of their similar cohort was still in 
treatment for their SUD.   
 It was hypothesized that those patients with PTSD would have a lower rate of 
adherence to buprenorphine and an increase in other drug use, especially opioid use.  
There is more than adequate evidence demonstrating that buprenorphine treatment 
contributes to higher retention in treatment, lower opioid use, lower other substance use, 
and lower mortality (D’Onofrio et al., 2017; Parks Thomas et al., 2014). Yet, despite this 
evidence, these findings are not evident when considering evidence of PTSD or a history 
of trauma.  The fact that those patients with PTSD in this study are more buprenorphine 
adherent than those without PTSD yet are also having higher percentages of opioid and 
other substance use, and meeting treatment compliance indicators highlights the major 
issue these patients are struggling to stay med compliant and their immediate needs are 
not being met. As their PTSD and trauma history are influencing their feelings of safety, 
possible loss of control, heightened anxiety levels, etc., they may not be fully ready to  
commit to full treatment compliance (US Department of Health and Human Services, 
2014).  
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PTSD and Buprenorphine 
 Surprisingly, patients with PTSD were more adherent to their prescribed 
buprenorphine regimen than those without PTSD.  Past research has shown that those 
with PTSD have had decreased adherence to buprenorphine (Kumari et al., 2016). This 
could be related to their increased number of encounters and shorter time since last seen.  
As they are seen more frequently by staff, the motivation to continue their medication 
treatment increases.  As this is the philosophy of this particular treatment center, this is 
validation that increasing visits and contact with staff when risk is elevated, has the 
benefit of increased medication adherence.  This is supported by previous work by 
Schacht, Brooner, King, Kidorf, & Peirce (2017) who found that the longer their 
participants stayed in treatment they reduced their positive urine screens for drugs and 
had less severe symptoms for those with PTSD.  Similarly, Meshberg-Cohen, Black, 
DeViva, Petrakis, & Rosen (2019) determined that those veterans in treatment for 
PTSD/OUD treatment that received concurrent therapy for trauma while receiving 
buprenorphine, resulted in an increased length of retention in their program with overall 
greater treatment success as a result.  
PTSD and Drug Use 
Those with PTSD did have a higher rate of opioid use than those without PTSD.  
These results suggest that while those patients with PTSD were still motivated to 
maintain their buprenorphine adherence, they still struggled to refrain from opioid use. 
As discussed in chapter 2, those patients with PTSD typically have a higher rate of opioid 
use than those without PTSD (Meier et al., 2014). This outcome is contrary to previous 
findings by Mills et al. (2018) that found at follow-up to treatment no baseline difference 
in heroin use based on PTSD status.    
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While this study used an amalgam of opioids as one indicator, which included 
prescription and non-prescription opioids, Meier et al. (2014) had similar findings in their 
study based on prescription opioids and the severity of other substance use among those 
with PTSD while in treatment.  In contrast to previous findings by Kumari et al. (2016), 
those with PTSD having used opioids during treatment also had a lower compliance with 
buprenorphine.  
Impact of Trauma on Treatment Compliance 
 Similar to the PTSD group, those patients with a history of trauma did show less 
treatment compliance throughout the same treatment indicators as well as increased drug 
use same as the PTSD group.  Those patients with a history of trauma had a lower rate of 
attending scheduled individual and group visits.   Consequently, they also did not attend 
meetings without notifying center staff, they rescheduled and cancelled group visits more 
often, had more encounters with staff, left care more often and needed more initial, 
induction, and rejoin visits.  As mentioned earlier as regards PTSD, the same is valid for 
patients with trauma histories.  Although they are staying more medication adherent with 
buprenorphine than those without trauma histories, they are also using opioids and other 
substances more, and missing the same treatment compliance indicators as those with 
PTSD.  This group is similarly struggling to stay within the program of medication 
adherence and treatment compliance.  
Similar to those patients with PTSD, those with a history of trauma, had the exact 
same treatment compliance results in terms of significant relationships between trauma 
and treatment indicators. Based on prior research, it is assumed that many of those with a 
trauma history in this study are also underdiagnosed as having PTSD (Elhai et al., 2012; 
Zimmerman & Mattia, 1999).   This may provide the explanation as to why these two 
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groups had the same results.  If in fact those with trauma also had undiagnosed PTSD, 
They may be experiencing similar symptoms and their specific needs in respect to 
needing trauma-informed care are simply not being met with just buprenorphine 
treatment.   
Impact of Trauma on Medication Adherence and Drug Use 
Trauma and Buprenorphine 
 Similar to the PTSD group, those with a history of trauma they were in fact more 
adherent to their scheduled medication than those without a history of trauma. While it 
was hypothesized that those with a history of trauma would also not be adherent to their 
buprenorphine, similar to the PTSD group, the reasons for this result are the same for the 
PTSD group.  Since those with a history of trauma were also less treatment compliant in 
terms of visits, they would have had more interaction with staff and would have been 
more focused and motivated to stay adherent to their medication schedule knowing they 
would be seen more frequently by treatment center staff.  
Trauma and Drug Use     
 While those with a history of trauma had similar drug use as those with PTSD, 
there were two differences.  Those with a history of trauma did not have a significant 
relationship to opioids and THC.  Reasons for this may be that while this group has 
experienced a traumatic event, they may not have developed a post-traumatic response 
and as a necessity tried to reduce symptoms associated with the sequelae of trauma.  It 
has been discussed in other studies that those affected in a traumatic way will at times use 
opioids and THC more as a means to self-medicate to try to reduce symptoms of anxiety 
related to trauma (Hassan, Foll, Imtiaz, & Rehm, 2017; Meshberg-Cohen et al., 2019; 
Saunders et al., 2015).  This may not be the case for this particular group of patients.   
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The Impact of CJS on Treatment Compliance 
 Those patients with CJS displayed less treatment compliance throughout the same 
treatment indicators as well as increased drug use similar to the PTSD/trauma groups.  
This was an expected outcome. As was discussed in chapter 2, those with an involvement 
in the criminal justice system often suffer from PTSD and experience trauma during their 
incarceration experience.  Additionally, those with CJS are also at a higher risk to enter 
incarceration having already experienced trauma and/or having a diagnosis of PTSD 
(Anderson, Geier, & Cahill, 2016; Harner, Budescu, Gillihan, Riley, & Foa, 2015; 
Kouyoumdjian et al., 2015). Similar to the PTSD/trauma groups, it was hypothesized that 
those patients with CJS would have a lower rate of attending scheduled individual and 
group visits.   
 Similar to those patients with PTSD/Trauma, those with CJS, had the exact same 
treatment compliance results in terms of significant relationships between CJS and 
treatment indicators.   One difference from the other two predictors was the addition of a 
significant relationship between CJS and no shows for group visits.  Upon further 
evaluation, even when controlling for age, race, time since last seen, total time in care, 
location, and ethnicity, there was no evidence of moderation between PTSD or trauma on 
CJS and group no shows.  A possible explanation for this difference may be that some 
people with criminal justice involvement that are in treatment SUD find it hard to share 
in group therapy situations and may prefer individualized treatment (Owens, Chen, 
Simpson, Timko, & Williams, 2018). 
 The inclusion of an interaction term also revealed a moderating effect of PTSD on 
CJS with regards to initial and induction visits.  It was not apparent in the literature that 
this relationship was examined previously.  One potential explanation is that again as 
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patients with CJS are also managing their PTSD symptoms, it may be that the PTSD 
itself is having an effect on their ability to stay focused in treatment and thus leaving with 
more frequency and having to have additional initial and induction visits similar to that of 
main effects relationship of PTSD to treatment compliance.     
Impact of CJS on Medication Adherence and Drug Use 
CJS and Buprenorphine 
 Unexpectedly, those with CJS were more adherent with their buprenorphine 
regimen.  It was hypothesized that again, the CJS group, like that of the PTSD/trauma 
groups would not be as adherent to their buprenorphine as the non-CJS group.  This may 
be due to a motivation to stay free of drugs and committed to their treatment due to the 
consequences of having to return to incarceration if they are found to be drug positive.  
As those with CJS increased the total time in care, there is also a significant decrease in 
opioid use. This finding is consistent with Gordon et al. (2015) and research on parolees 
and probationers who were in medication treatment for OUD.   
CJS and Drug Use 
 Another unexpected result was that the CJS group had less drug use than expected 
compared to the non-CJS group especially as it pertains to opioids and methadone.  The 
CJS group had significantly less percentage of opioids and methadone than the non-CJS 
group.  This again suggests that not only is there a motivation to stay free from 
incarceration, but potentially the preference for more may be protective from drug use.  
This finding supports observations by Fox et al. (2015) who conducted a small number of 
interviews with patients who had previously been incarcerated and were either presently 
in treatment for OUD or had been in the past.  They found that these patients preferred 
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medication treatment over abstinence-based recovery.  Furthermore, they not only 
preferred medication treatment, but also favored buprenorphine over methadone.  
 CJS was evaluated with PTSD and trauma as potential moderates and found that 
both PTSD and trauma moderated that effect that CJS had on increasing buprenorphine 
adherence and a slightly higher use of opioids over the non-PTSD and non-trauma 
groups.  As mentioned previously, these results mirror the PTSD and trauma main 
effects.  The most interesting of these results is that of the moderation effect on opioids.  
While those with PTSD but without CJS are using opioids significantly less than the non-
PTSD group as in the main effect, once CJS is added, there is a significant reduction in 
use of opioids for the non-PTSD group which is concurrent with the previous evaluation 
of CJS main effects, but the PTSD group slightly increases their opioid use.  This again 
shows that even with the motivation of staying free of opioids in the CJS group, this isn’t 
enough to override the need to still use opioids once PTSD is added.  This is additionally 
another measure that needs to be accounted for during and before release from 
incarceration.  If this group had been evaluated for both OUD and PTSD and trauma at 
the same time on admission and treated appropriately, we may see that the CJS with 
PTSD group stays at the same level of opioid use.   
Impact of Gender on Treatment Compliance 
 When evaluating treatment compliance by gender, there were noted differences 
between men and women.  Women, similar to those with PTSD and histories of trauma, 
are being underserved within this treatment modality.  Again, while there was no 
difference in medication adherence, there were still more instance of failed treatment 
compliance, and other drug use.  As noted previously, women had the highest 
percentages of PTSD and trauma, which may contribute to some of these issues.   
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Gender was combined with trauma to evaluate moderating effects and found that 
trauma did moderate the effects of no-show visits, rescheduling, and more encounters, 
with women always having higher rates than men.   A similar interaction was evaluated 
for CJS and gender and found that the effects of CJS on gender.  With many people 
within CJS groups experiencing trauma before and during incarceration, this could be the 
reason for the same effect.  It is still apparent that women are struggling as well and need 
more directed care with a focus on trauma specific treatment.   
There were noted differences in gender as a predictor than the other three 
predictors (PTSD, trauma, and CJS).  There were no gender differences in the attendance 
to maintenance visits, which is  similar to findings by McHugh et al. (2013) that found no 
gender differences in attendance at treatment sessions.  Women spent more time in care 
than men which is supported from previous research (Evans et al., 2015).  Women were 
more likely to have more no shows, no show group visits, cancel group meetings in the 
CJS group, and reschedule visits more.  One explanation for this may simply be social 
functioning of women compared to men.  A study of gender differences in OUD 
treatment by Bawor et al. (2015) revealed that while women were less likely to be 
employed then men, they were three times as likely to be caring for children.   Another 
explanation could be that as 13.4% women had a PTSD status and 17.0% of women had a 
trauma history, there may be a reluctance to attend both individual and group treatment 
sessions for fear of stigma, anxiety, or embarrassment.  However, this may not overtly 
affect their ability to maintain the same use of buprenorphine and use of opioids as men.  
As  Sokol, LaVertu, Morrill, Albanese, & Schuman-Olivier (2018) pointed out after a 
large systematic review of studies based on group therapy based treatments for OUD 
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patients, there does not appear to be a large-scale significance for outcomes based on 
group therapy for those with OUD.   
Impact of Gender on Medication Adherence and Drug Use 
 Evaluating medication adherence and drug use by gender revealed differences 
between gender and the three other predictor variables.   
Gender and Medication Adherence  
The relationship between gender and buprenorphine adherence was not 
significant.   
Gender and Drug Use 
Women showed an increased use of benzodiazepines and amphetamines (among 
trauma and CJS groups) which is consistent with previous findings (Bawor et al., 2015).  
The use of amphetamines if particularly alarming as research by Evans et al. (2015) 
revealed the concurrent use of amphetamines and opioids contributes to an increase in the 
hazard risk for death for women that are in treatment for OUD.     
Men had a significant increased use of THC and alcohol.  Bawor et at. (2015) also 
determined that THC use was higher in men, however, they did not determine any gender 
differences for alcohol.  This present study found alcohol to be higher by positive urine 
screen in men.    
Application to Theory 
 As previously noted in chapter 2, Lazarus and Folkman’s (Lazarus & Folkman, 
1984) Transactional Stress theory informed the study by providing a framework to view 
stress, appraising stress, and coping with stress as a goal focused toward long-term 
adaptation to stress.  These stress indicators were not measured, but rather assumed under 
the operationalized variables of PTSD, trauma, and CJS.  The initial reason for choosing 
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this theory was based on the prevalence within the literature suggesting that a large 
proportion of those with an OUD were using opioids and other substances as a way to 
reduce stress or in response to stress from trauma.  The transactional stress theory 
appeared to fit well within the realm of opioid use while managing PTSD, a history of 
trauma, a past incarceration experience, or the presence of all three.  As discussed in the 
literature review, all three of these situations has the ability to create a larger stress 
dynamic for the patient through an increase in anxiety and other psychosomatic responses 
to stress.   Lazarus and Folkman regard the ideal coping method as a series of appraisals 
followed by conscious decision making to react in an adaptive way.  
The chronic brain disease model of addiction suggests that those with OUD using 
opioids and other substance continue to disrupt decision-making and self-control neural 
processes within the brain (Baler & Volkow, 2006; NIDA, 2018).  This disruption makes 
it more difficult to make pertinent decisions related to controlling one’s use of substances 
in relation to events in their life (Smith, Mattick, Jamadar, & Iredale, 2014; Volkow & 
Morales, 2015).  This is similar to the transactional stress theory that theorizes a stress 
response to a specific event in life.  As hypothesized in Chapter 2, for those with PTSD, 
CJS, or trauma, a successful coping strategy would be for those patients to employ a 
problem-based method to solve their stressful situation.  The optimal end result would be 
free of drug use as a consequence that benefits not only short-term gains but can 
cumulatively function as building a long-term physical and cognitive response to stress 
without opioids or other drug use.   
The transactional stress theory is complementary to the chronic disease model as 
viewed through this study.  Framing the study through transactional stress theory, it 
suggests that potentially, the patient’s brain is learning to sustain itself with markedly less 
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opioids with the use of buprenorphine, the patient is also making repeated appraisals 
which neurobiologically is redefining neural connections to learn to cope more 
effectively without opioids (Volkow, Koob, & McLellan, 2016).  Within this study 
though, for those with PTSD and trauma, as an example, we can view two responses to 
stress.  The increase in maintenance visits for those with PTSD and trauma, than those 
without, could be viewed as evidence that when combined with medication treatment 
(MT) there is an adaptive coping strategy being employed in light of the stress, which 
will hopefully lead to long-term adaptation.  However, there is also the increase of use of 
opioids for those with PTSD and trauma than those without.  This is reflective of poor 
decision making as a result of assumed stress and maladaptive coping strategies utilized 
by patients with PTSD, trauma, and a CJS.   
In regard to treatment compliance, all three predicator variables have similar 
significance and direction in terms of compliance indicators.  For those three predictor 
groups, missing maintenance visits without notice, leaving treatment and then rejoining 
and having to have more initial and induction visits, are all consequences of appraisals 
based on stress and control. Those visits present several possibilities of stress for the 
patients that begins the process as a causal antecedent.  Failing to meet those compliance 
indicators could be because the person is worried about having to provide a urine sample 
knowing it will produce positive results for drug use.   
An explanation for this is that those patients are anxious about attending an 
individual session with a provider and having to talk or re-live a traumatic experience.  
There could be an element of shame and stigma that is holding a patient back from 
attending these visits.  These are results of false or negative appraisals that allow the 
patient to revert back to place of wanting to maintain control for fear of harm or trauma.  
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As these patients miss more meetings and need to induct themselves to treatment, we can 
view their subsequent attendance as a positive appraisal that have resulted in their ability 
to attend these visits and to be safe and unharmed.   
Those patients with PTSD/trauma/CJS showed maladaptive coping skills in their 
use of opioids, THC, cocaine, benzodiazepines, and amphetamines. It is clear that upon 
primary appraisals of stress during their treatment they have still reverted back to using 
opioids or other drugs. However, they are still maintaining adherence to their 
buprenorphine treatment more than those without PTSD/trauma/CJS, which over time 
may allow these groups of patients to benefit from long-term effects of continuing 
treatment with buprenorphine, while reducing their use of opiates and other drugs.  This 
has the potential benefit of long-lasting recovery, improved mental health, reduced 
mortality, improved social functioning through long-term adaption to life stressors.   
One particular example of Lazarus and Folkman’s concept of problem-focused 
coping is the success of the CJS group to use opioids less than those without CJS and 
have a higher rate of buprenorphine use.  Re-entering their communities after 
incarceration increases stress and risk for relapse (Binswanger et al., 2012; Wakeman, 
2017).  When encountering stress in their lives, these individuals appear to be attending 
to the situation from a problem-focused position. This process may include cognitively 
appraising the consequences of using opioids again and not adhering to their medication 
treatment, which may result in their return to incarceration (Matusow et al., 2013).   This 
increased vigilance may offer the patient the needed focus to problem solve effectively, 
which is enhanced due to the addition of medication treatment which will also reduce 
cravings and additional reduction of symptoms from reduced opiate use.   
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This raises more questions if looking at transactional stress within the realm of a 
chronic brain disease model for addiction for those CJS patients. If this is a lack of 
adaptive coping, self-control, and inappropriate decision making, how is it that those 
within the CJS group are able to override that and not rely on opioids?  Applying this 
theory to CJS patients in this manner supposes the implication of psychological stress on 
those patients when in fact those may be simply weighing a cost-benefit analysis of 
staying opioid free to stay out of jail or prison.  Theories and concepts of motivation, 
control, community risk factors, or punitive justice/treatment policies warrants further 
study especially in light of the findings of this study.   
Implications for Nursing Practice 
 As this study has confirmed, those with PTSD, a history of trauma, and a past 
involvement in the criminal justice system, can have very significant and lasting 
consequences that impact treatment compliance and medication adherence for those with 
OUD. The Substance Abuse and Mental Health Services Administration (SAMHSA) 
states that it is imperative that treating trauma should be a primary goal when treating a 
person with co-occurring OUD/PTSD or history of trauma (US Department of Health and 
Human Services, 2014).  Advance practice nurses and physicians in various practices are 
not accepting enough patients even when they have not met their designated capacity to 
take on patients utilizing buprenorphine (Huhn & Dunn, 2017).    Presently, there is a 
need for nurses and nurse practitioners to care for those with OUD and co-occurring 
mental health disorders.  The American Association of Nurse Practitioners (AANP) 
educates Nurse Practitioners on the practices of prescribing MT to patients and lowering 
the risk of overuse of opioids for patients.  The education outline on their website is 
titled: Opioid Risk Evaluation and Mitigation Strategy Resources (REMS).  Of concern is 
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that this lacks any mention of assessing for trauma, PTSD, or past experiences that may 
involve trauma such as a criminal justice history, veteran, or refugee status as potential 
risks (AANP, 2018).   
If nurse practitioners and nurses are to be trained to successfully to treat those 
with an OUD, they need to assimilate a model of trauma-informed care for their patients 
and not only assess prior opioid use, but past trauma.  This omission of treating those 
with trauma is not only absent here but also with the American Society of Addiction 
Medicine (ASAM).  In the published clinical guidelines of practice for the ASAM, the 
only mention of trauma or PTSD is in relation to assessing for other co-morbid diagnoses 
during the history and physical (American Society of Addiction Medicine, 2015). While 
this is a positive step, the manual lacks any mention of what the clinician, nurse, or team 
member should do if the patient screens positive for these and how to then develop a 
course of treatment that reflects these potential risks to reduced treatment compliance.  
Nurses are poised to be at the forefront of addiction treatment, especially as it 
relates to those with OUD that also have a history of trauma.  As Moller & McLoughlin 
(2013) assert, the fundamental core nursing philosophy is congruent with that of trauma-
informed care.  Moller & McLoughlin (2013) remind us that the American Nurses 
Association (ANA) definition of nursing practice is:  
Nursing is the protection, promotion, and optimization of health and abilities, 
prevention of illness and injury, alleviation of suffering through the diagnosis and 
treatment of human response, and advocacy in the care of individuals, families, 
communities, and populations. (American Nurses Association, as cited in Moller 
& McLoughlin, 2013) 
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This definition also reflects the key tenets of SAMHSA’s framework for trauma-
informed care which include safety, trustworthiness and transparency, peer support, 
collaboration and mutuality, empowerment, voice, cultural, gender issues (US 
Department of Health and Human Services, 2014).  Nurses have the ability to not only 
fulfill this framework set forth by SAMHSA, but also have the ability to advocate that all 
clinicians and personnel working within addiction treatment work from a trauma-
informed care perspective.   
While there are numerous modalities to choose from, nurses have the ability to 
work from a perspective of trauma-informed care.  Working from a trauma-informed care 
perspective means that a clinician understands how pervasive trauma exists in our 
patients and communities, grasps the affect that trauma has on people, groups, various 
societal systems, and takes this understanding and utilizes it to deliver care to the people 
that are affected by trauma (US Department of Health and Human Services, 2014).  
Viewing OUD as chronic disease, facilitates nurses’ ability to assist patients within a 
trauma-informed care model.   Furthermore, nurses are within a position to provide the 
long-term, sustained care that these patients need.   
One example of a model where nurses can be pivotal members of the treatment 
team was developed in Massachusetts over the past 10-years in the Office-Based Opioid 
Treatment -collaborative model (OBOT-B) utilizing buprenorphine (LaBelle, Han, 
Bergeron, & Samet, 2016). This model is led with a nurse care manager assigned to each 
patient that provides assessment, induction, education, drug/alcohol assessment, follow-
up maintenance visits, and general counsel throughout their treatment program.  This is 
followed under the direction of a physician; however, the model recognizes that nurses 
are better positioned to spend more time with the patient, have less of a case-load than the 
 137 
physician, and as mentioned earlier, have a philosophical grounding that allows them to 
attend holistically to the patient.   While this program is an exemplar, it still lacks a 
focused assessment and further con-current treatment of OUD and trauma with a trauma-
informed care model.   
No matter the model of choice, at the very least, it should include both nurses and 
nurse practitioners working in tandem with other clinicians and team members that 
function from a trauma-informed care perspective.  This means that first and foremost as 
nurses proceed into addiction medicine, they learn as much about the antecedents of 
trauma and the sequelae from trauma as possible.  These nurses should be relied on to 
assess all patients universally for a history of trauma,  and then make the determination 
whether the patient needs a specific trauma informed approach.   
If possible, keeping that same nurse/patient relationship would be essential for 
developing a sense of belonging, trustworthiness, and safety.  As the patient progresses, it 
will be of great importance for the nurse to praise the patient when meeting all treatment 
compliance indicators and be yet very empathetic and empowering when the patient may 
have missed a compliance indicator or had another drug appear on a urine screen for 
instance.  By doing this the nurse will allow the patient to make mistakes, yet still feel 
empowered to resume treatment.    
Limitations to the Study 
Data Mining 
One limitation is related to the utilization of data mining procedures.  Had the 
electronic health record (EHR) been designed in a manner to easily gather data, this may 
have given the study the ability to derive a more robust analysis of the data.  For instance, 
finding clinician input of PTSD and trauma symptoms resulted from pulling data from 
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multiple locations in the EHR.  If there was a formalized place to score patients as they 
were assessed, there may have been an even greater number of patients identified with 
PTSD or trauma histories as this is an often underdiagnosed group to begin with (Elhai et 
al., 2012; Zimmerman & Mattia, 1999).    
Motivation 
An additional limitation is the inability to understand the motivation for treatment 
success for CJS patients. Those CJS patients may have been involved in a drug treatment 
court (DTG) or simply had an understanding that if found to having been using opioids, 
they would be in violation of a probation or parole status.   The motivation to avoid re-
incarceration is plausible but cannot be known as a result of this study.  If this was their 
motivation, this is concurrent with current literature that demonstrates that recidivism of 
those in DTC’s has been shown to decrease for those with increased supervision, MAT, 
and therapy (DeFulio et al., 2013; Jewell, Rose, Bush, & Bartz, 2017; Sevigny, Fuleihan, 
& Ferdik, 2013; Shannon, Jones, Newell, & Neal, 2018).  It should be noted that the 
recidivism measured in these previous studies, with the exception of DeFulio et al. 
(2013), is not based on opioid or drug use at follow-up, it is based on withdrawal from a 
DTC program, reincarceration, or criminal offense.  Following up for long-term periods, 
even past probation or DTC enrollment, would help provide useful data to determine if 
opioid use stays low after those initial motivations i.e. not returning to jail or prison, have 
expired.   
Pre-release Medication Treatment 
A final CJS-related limitation is the inability to know if participants with CJS had 
initiation to buprenorphine pre-release from incarceration. While the instances of 
receiving buprenorphine pre-release from incarceration are limited, it is possible that 
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some CJS patients may have received medication treatment pre-release.  Gordon et al. 
(2017) found that at 12-months post-release, those patients who had received 
buprenorphine pre-release displayed increased buprenorphine use and longer time in 
treatment.  Due to this finding, it would be beneficial to know if some of those in the CJS 
group received buprenorphine pre-release and therefore increased their treatment success 
in this study.    
As previous research has demonstrated that the longer the period of abstinence 
from opioids (except buprenorphine or methadone), at least 5-years, the greater chance 
patients have of long-term abstinence (Hser, Evans, Grella, Ling, & Anglin, 2015; Zhu et 
al., 2018).  Evaluating these patients for only a two year period may have limited the 
ability to view long-term recovery.   
Sample Characteristics 
In regard to the sample, though a relatively large sample size was used, a limiting 
factor was the homogenous makeup related to a mostly white, non-Hispanic, mostly from 
Massachusetts sample. Additionally, it was not known from the sample data whether the 
patients in the sample were managing an OUD from heroin or prescription opiates.  Black 
and Hispanic patients with an OUD are disproportionately suffering from an addiction to 
heroin and not prescription opioids (Krawczyk, Feder, Fingerhood, & Saloner, 2017).  
Earlier studies demonstrated that those in poverty, people of color, Hispanic ethnicity, 
without a college education, and having an addiction to heroin were more likely to 
receive methadone than buprenorphine (Hansen et al., 2013; Hatcher, Mendoza, & 
Hansen, 2018).  Recent studies have shown an increase in healthcare utilization for those 
with an OUD both nationally after the implementation of  the Affordable Care Act 
(McKenna, 2017) and within Massachusetts after implementing a universal care model.  
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However, despite these increases, black and Hispanic patients are still underserved in 
terms of receiving buprenorphine treatment for OUD (Krawczyk et al., 2017).  
Questions for Future Research 
The findings suggest further study focused on whether the motivation for CJS 
patients to be med adherent and less reliant on opioids is not being reincarcerated.  This 
may prove helpful to understand this motivation as we see an increase in the use of drug 
courts and provide further evidence to those who would have us only treat those patients 
with abstinence-based treatments and further incarceration. Further theoretical models 
should be examined and adapted to direct evidence-based practice regarding CJS patients.   
As mentioned earlier, knowing whether or not CJS patients have received 
buprenorphine during incarceration would help provide further credence that this 
population needs to be treated while incarcerated not only immediately before re-entry 
but at the beginning of the incarceration experience.   
Finally, it would be important to understand the impact of PTSD treatment on the 
impact of MT treatment on patients with PTSD.  Future research should examine both of 
these constructs simultaneously. Understanding the individual and group counselor’s 
theoretical approach may help elucidate if patients with PTSD have better MT outcomes 
with or without specific PTSD treatment.  It would also be beneficial to understand if 
there is an impact of PTSD treatment type as this could help direct care for other patients 
with similar circumstances.   
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Conclusions and Implications 
This study confirms that those with PTSD, trauma, or a CJS are at increased risk 
for not only missing and withdrawing from treatment but are requiring far more attention 
from treatment center staff to manage their recovery.  The particular system of patient 
management that this particular treatment center utilizes appears to have a successful 
model that is improving the health of their patients, even those with PTSD, trauma, or 
CJS.   Those with PTSD/trauma/CJS are continuing to be medication adherent while at 
the same time still using other drugs and missing treatment visits.  This suggests that 
these groups are struggling to continue their treatment despite accessing additional help 
from staff.  Additionally, women are a seeming to have the same issues in terms of 
treatment compliance and need further study to direct care that is supportive to this 
specific group of patients.  The development of interventions specifically focused on 
PTSD/trauma and CJS experiences would help mitigate this disruption in care.   
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APPENDIX B 
 
 
OPIOID DIAGNOSTIC CRITERIA 
 
1. Opioids are often taken in larger amounts or over a longer period than was intended. 
2. There is a persistent desire with unsuccessful effort to cut down or control opioid use.  
3. A great deal of time is spent in activities necessary to obtain the opioid, use the opioid, or 
recover from its effects.  
4. Craving, or a strong desire or urge to use opioids.  
5. Recurrent opioid use resulting in a failure to fulfill major role obligations at work, school, or 
home.  
6. Continued opioid use despite having persistent or recurrent social or interpersonal problems 
caused or exacerbated by the effects of opioids.   
7. Important social, occupational, or recreational activities are given up or reduced because of 
opioid use.  
8. Recurrent opioid use in situations in which it is physically hazardous.  
9. Continued opioid use despite knowledge of having a persistent or recurrent physical or 
psychological problem that is likely to have been caused or exacerbated by the substance.  
10. Tolerance as defined by the following:  
a. A need for markedly increased amounts of opioids to achieve intoxication or 
desired effect.  
b. A markedly diminished effect with continued use of the same amount of an 
opioid.   
11. Withdrawal as manifested by the following:  
a. The characteristic opioid withdrawal syndrome.  
b. Opioids (or a closely related substance) are taken to relieve or avoid withdrawal 
syndrome.   
(Diagnostic and statistical manual of mental disorders : DSM-5. (APA, 2013).  
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